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ABSTRACT 
 
Herpes simplex virus type 1 (HSV-1) is a ubiquitous human pathogen that establishes a 
latent infection in sensory ganglia and upon reactivation, can cause severe ocular disease. During 
lytic replication, viral proteins are expressed in a temporal cascade of immediate early (α), early 
(β) and late (γ) genes. The γ genes are further sub-classified into γ1 genes which are expressed 
prior to DNA replication and γ2 genes which are absolutely dependent on DNA replication for 
their expression. During a latent infection of the trigeminal ganglia (TG), no infectious virus is 
produced and latency is associated with a persistent virus-specific CD8+ T cell infiltrate that 
actively block reactivation. In C57BL/6 mice, approximately 50% of these CD8+ T cells are 
specific to a single epitope on a γ1 protein glycoprotein B (gB498-505; gB-CD8). In the TG, gB-
CD8 are retained with an activated phenotype suggesting recent exposure to antigen during 
abortive reactivation events. While the kinetics of gene expression during lytic infection has been 
appreciated for some time, little is known about antigen expression during latency and 
reactivation, and its influence on antigen-specific CD8+ T cells in the TG.  Using gB as our 
model antigen, in this work we show that during reactivation, gB expression occurs much sooner 
than gC expression, indicating that it expressed fairly early even during reactivation. 
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Furthermore, by delaying gB expression to after DNA replication we observed a severe 
impairment in viral replication in the TG and a significant diminishment in the retention and 
activation phenotype of gB-CD8 in latently infected TG. However delaying gB did not prevent 
the ability of gB-CD8 to block reactivation indicating they can act very quickly even after DNA 
replication. Finally we demonstrate that by mutating the gB epitope such that it does not induce a 
gB-CD8 response, we abrogate the gB-CD8 infiltrate in the TG. These studies all demonstrate 
that during an HSV-1 infection, only antigen-specific CD8+ T cells infiltrate the TG and antigen 
exposure during latency is responsible for their retention in the TG. This work has great 
implications toward designing better immunogens for therapeutic vaccines to prevent HSV-1 
reactivation. 
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1.0  INTRODUCTION 
1.1 HERPES SIMPLEX VIRUS TYPE 1  
1.1.1 HSV-1 Disease and Epidemiology 
Herpes simplex virus type 1 (HSV-1) is a human herpesvirus that is classified under the family 
Herpesviridae and sub classified as Alphaherpesvirinae, along with HSV-2 and varicella zoster 
virus (VZV). All the human Alphaherpesviruses are neurotropic, infecting multiple cell types 
during primary and reactivated disease, but establish latency only in the sensory ganglia 
innervating the sites of infection (135). The ubiquitous nature of HSV-1 makes it such that 
around 80% of the world’s population has been exposed to the virus (152, 184).  In the United 
States, approximately 57% of individuals between the ages of 14 and 49 are seropositive for 
HSV-1 and this number rises to over 90% after the age of 60 (141, 170). HSV-1 is usually 
transmitted via oral contact or droplet spread, and is often contracted during early childhood 
(184). While primary infections are often more serious than reactivated disease, they can often be 
asymptomatic, leading to many people being unaware of the initial infection. Reactivated disease 
is of variable clinical presentation ranging from visible disease to asymptomatic shedding. HSV-
1 reactivation can cause several diseases including cold sores, gingivostomatitis, herpetic 
whitlow, genital lesions, encephalitis as well as blinding stromal keratitis (184). 
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1.1.2 Herpes Stromal Keratitis 
HSV-1 can infect the corneal surface and lead to a latent infection in the trigeminal ganglia (TG). 
Reactivation of the virus from the ophthalmic branch of the TG results in recrudescent disease at 
the corneal surface that can manifest itself in several forms including blepharitis, conjunctivitis, 
epithelial keratitis, and herpes stromal keratitis (HSK).  HSK is a severe immunopathological 
disease that results from HSV-1 reactivation and viral replication in the cornea. Approximately 
500,000 individuals suffer from HSK in the United States with 300,000 new cases reported every 
year (86). Reactivation of HSV-1 and subsequent viral replication at the corneal surface results 
in an immune infiltrate into the eye aimed at controlling viral replication. The infiltrating 
immune cells release several factors, such as the cytokines γ-interferon (IFNγ) and interleukin-2 
(IL-2), and other compounds, including nitrous oxide (NO) and matrix metalloproteinases, that 
can cause destruction and disorganization of the collagen matrix of the stroma, eventually 
leading to scar tissue formation and blindness (9, 82, 110). Therapies for HSK include 
prescription of antiviral drops in conjunction with corticosteroids to reduce viral replication and 
inflammation respectively (4, 23). However, antiviral treatments are only effective in the face of 
ongoing viral replication and HSK can develop in the absence of infectious virus in the cornea 
(43). Treatments with steroidal compounds also have side-effects and cannot reverse the effects 
of HSK. HSV-1 is the leading cause of infectious blindness in the developed world (56, 85-86). 
Blindness resulting from HSK is also the leading cause for corneal transplants in the United 
States alone and approximately 5-10% of corneal transplants are performed on patients with 
HSK to restore sight (132). Furthermore, recurring HSK can also cause corneal graft rejections 
amongst corneal transplant patients and alternatively, HSV-1 may be acquired from donor tissue 
(132-133). The lack of an effective treatment or vaccine for primary or recurrent HSV-1 
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infections makes it a pathogen of great public health relevance and one that warrants further 
research.   
1.2 HSV-1 STRUCTURE  
The HSV virion can be represented as four morphologically distinct compartments: (a) an outer 
envelope with glycoprotein spikes on its surface, (b) a tegument layer containing 25-30 viral 
proteins, (c) an icosahedral capsid just beneath the tegument layer and (d) an electron opaque 
core encompassing the HSV genome (Fig. 1-1) (184). 
 
 
 
Figure 1-1 Graphical representation of the HSV-1 virion. 
The HSV-1 nucleocapsid (blue) contains one genome length of double stranded viral DNA within 
it. The capsid is surrounded by a proteinaceous tegument layer (purple) which is enclosed within 
a host derived envelope containing viral glycoprotein spikes (green and red). The diagram is not 
to scale.  
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The HSV-1 virion contains a linear double stranded DNA genome of approximately 152 
kb that is packaged within the icosahedron shaped capsid. The DNA consists of two unique 
segments known as the unique long (UL) and the unique short (US) segments (Fig. 1-2). These 
unique segments are flanked on either end by inverted repeats referred to as RL and Rs 
respectively for the long and short repeats. The RL repeat sequences are denoted as ab and b’a’ 
and the RS repeats are denoted as a’c’ and ca (Fig. 1-2). The UL and US segments can invert 
relative to each other, thus forming four linear isomers which can all produce viable virus 
particles. The entire HSV-1 genome encodes for the expression of approximately 80 viral 
proteins (135, 182).  
 
 
 
Figure 1-2. Representation of the HSV-1 genome organization. 
The HSV-1 genome is separated into a unique long (UL) and unique short (US) segments flanked 
by inverted repeat sequences ab, b’a’c’ and ca. The diagram is not to scale. Figure is adapted 
from (184). 
 
1.3 HSV-1 LIFE CYCLE 
HSV-1 can adopt two modes of infection, a lytic phase and a latent phase. During the lytic stage, 
virus amplification leads to the eventual lysis and death of some but not all types of infected 
cells. The virus can also enter a latent phase, exclusively in neuronal tissue, during which the 
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viral genome can persist for indefinite periods of time within the infected neuron. HSV-1 can 
then periodically re-enter the lytic cycle from latency, a phase known as reactivation whereby 
newly produced virus particles can result in recrudescence of disease.  
1.3.1 HSV-1 Entry 
Viral replication begins with HSV-1 entry into a permissible host cell. This requires attachment 
to receptors and the fusion of the virus’ membrane and the host cells’ lipid membrane. Three 
viral glycoproteins, glycoproteins B, C and D (gB, gC and gD) mediate viral attachment, binding 
and entry. Initial attachment of the HSV virion is mediated by the binding of glycoprotein C (gC) 
to heparan sulfate moieties on cell surface proteoglycans (HSPGs) (53, 148). gC is not essential 
for entry and in its absence, gB can bind directly to HSPGs (52). However, binding of gC to 
heparin sulfate confers a higher efficiency for gD to bind to other cell surface co-receptors such 
as Herpesvirus entry mediator (HVEM), transmembrane adhesion molecules, nectin 1 α or β or 
3-O-sulfated heparan sulfate, depending on the cell type. The virus then enters the cell following 
binding of gD to one of its high affinity receptors followed by a fusion event that requires gB and 
the gH/gL complex along with gD (172).  
1.3.2 Lytic Replication 
1.3.2.1 Gene expression pattern 
During the HSV-1 lytic cycle, over 80 viral genes are expressed in a tightly regulated temporal 
cascade (Fig. 1-3). Following entry, the viral nucleocapsid along with some tegument proteins is 
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transported into the host cell nucleus. Once the nucleocapsid reaches the nucleus, the viral DNA 
is ejected into the nucleus and transcription of viral proteins can begin. 
The immediate early (IE or α) genes are the first to be expressed and can be transcribed 
in the absence of de novo viral protein synthesis, whereas the early (E or β) genes and the late (L 
or γ) genes are expressed only following α protein expression. The immediate early genes 
encode proteins involved in transcription of other viral genes. The early genes encode proteins 
that are responsible for viral DNA replication while the late genes mainly glycoproteins and 
factors required for virion assembly egress and maturation. Following the expression of all the 
classes of proteins, infectious virus can be assembled and released from the infected cell (135). 
 
 
 
Figure 1-3. HSV-1 lytic gene expression kinetics.   
The general pattern of gene expression during HSV-1 lytic replication is shown. The first genes to 
be expressed are the α genes (purple) followed by the genes (blue). Accumulation of β proteins 
signifies the beginning of DNA replication (dotted line) following which the γ genes can be 
expressed. The γ genes are split into two categories, γ1 (orange) and γ2 (green). γ1 genes can be 
made prior to DNA replication in small amounts while γ2 genes require DNA synthesis before 
they can be expressed. Once all protein classes have accumulated, progeny virus (red) can be 
assembled and released from the infected cell.  
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Immediate early gene transcription begins soon after viral entry and IE proteins 
expression peaks around 2 to 4 hours post infection (h.p.i). There are five IE proteins encoded by 
HSV-1 and they are ICP0, ICP4, ICP22, ICP27 and, ICP47. All the IE proteins besides ICP47 
can regulate gene expression and functional IE proteins are essential for the transcription of other 
gene classes. ICP0, is an E3 ubiquitin ligase encoded by HSV-1 and while it is not essential to 
viral growth, it is important for optimal replication especially in low multiplicity infections and 
efficient reactivation from latency (49). ICP0 is also involved in counteracting the host defense 
against viral infection, including suppressing the interferon response and degradation of various 
cellular proteins (35, 38, 91, 107-108). One of the most important and extensively studied IE 
proteins is ICP4. ICP4 is indispensable to HSV-1 replication and is required for the activation of 
both early and late genes (180). ICP4 can also function to repress the expression of some viral 
genes including its own gene (32, 119). A role for IE protein ICP22 has also been implicated in 
altering the localization of cellular proteins into distinct nuclear foci containing ubiquitinated 
proteins and proteasomal components. (6). ICP27 is another IE protein that is indispensable for 
viral replication. Many important functions have been attributed to ICP27 including its 
involvement in the switch from early to late gene expression, inhibition of mRNA splicing, RNA 
binding, and transport of intronless viral mRNA out of the nucleus (182). Finally, ICP47 has 
been shown to be involved in immune evasion of the virus from the host immune response by 
downregulating antigen presentation through major histocompatibility complex  I (MHC class I) 
expression by blocking the transporter associated with antigen processing (TAP) protein function 
(54, 118).  
The early or β genes are expressed following the accumulation of α proteins and their 
expression peaks around 5 to 7 h.p.i. Early genes encode proteins that are responsible for DNA 
replication including thymidine kinase (tk), DNA polymerase, ribonucleotide reductase and 
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single stranded DNA binding protein. Expression of early proteins results in the onset of DNA 
replication following which the γ genes can be expressed. Late gene expression peaks typically 
between 8 and 12 h.p.i, although some proteins can be detected much earlier during infection.  
The γ genes can be separated into two subclasses, γ 1 and γ 2. Typical members of the γ 1 gene 
class such as glycoproteins B and D (gB and gD) are expressed fairly early during infection and 
their expression is only moderately affected by drugs inhibiting DNA replication. γ 2 genes such 
as gC and gH are expressed only following DNA replication and their expression is abrogated in 
the presence of DNA replication inhibitors. The late genes encode mainly structural proteins that 
are required for assembly of fully functional progeny virus (135). 
1.3.2.2 Regulation of gene expression 
The temporal regulation of HSV-1 gene expression is dictated largely by the different 
promoter composition for each gene class. The incoming virus is dependent on a tegument 
associated protein, VP16 to initiate transcription of IE genes. The VP16 that is brought in with 
the virion binds to two cellular proteins, HCF and Oct1, which together form the VP16-induced 
complex. This complex is able to bind to the TAATGARAT sequence uniquely present within 
the upstream region of each IE promoter to initiate gene transcription.  IE gene expression is also 
further regulated by several cis-acting regulatory elements including the presence of several 
binding sites for a cellular transcription factor SP1, TATA box and in some IE genes, a binding 
site for ICP4 which can repress gene expression (Fig. 1-4 A).  
Early gene promoters do not have elements required for VP16 binding; their promoters 
contain only sites for SP1 binding and TATA and CAAT elements (Fig. 1-4 B). While early gene 
promoters appear to have all the cis-acting elements required for transcription, they are not 
transcribed until IE genes have been made. Studies of the early tk gene promoter have shown that 
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functional ICP4 is required for transactivation of this gene (62). While there are no particular 
features of the TATA element that are specific to early genes, the strength of ICP4 binding to the 
TATA box seems to confer expression levels rather than kinetics (25).  
The onset of DNA replication appears to be the major switch from early to late gene 
expression. The late gene promoters also contain all the cis-acting elements needed for gene 
expression (Fig. 1-4C). However, late genes still require ICP4 interaction with the TATA 
elements present within the late promoters for their transcription. In contrast to IE and E genes, L 
genes also contain regulatory elements downstream of the TATA box including an initiator 
element at the start of the transcription site as well as a downstream activation site that is 
necessary for maximal expression (Fig. 1-4C).  This feature of HSV-1 to temporally regulate 
various gene classes by virtue of promoter composition differences makes it possible to generate 
a variety of recombinant viruses in which either viral or non-virally encoded proteins can be 
driven from an HSV-1 promoter from any gene class (31). 
 
 
 
 
 
 
 
 
 
 
 
 10 
 
 
 
 
 
Figure 1-4. Schematic of HSV-1 promoter structures.  
A schematic representation of the general arrangement and composition of cis-acting regulatory 
elements within HSV α,  β, and γ promoters is shown. The actual number and arrangement of 
elements varies among promoters of each class. (A) In addition to the TATA element, IE 
promoters have TAATGARAT elements in the upstream region through which the viral VP16 
protein mediates transcriptional activation. Binding sites for eukaryotic transcription factors such 
as SP1 are also present upstream from the TATA element, and in at least some IE promoters, 
binding sites for ICP4. (B) Early promoters have binding sites for eukaryotic transcription factors 
upstream of the TATA element but no identified cis-acting regulatory elements further 
downstream. (C) Late promoters have an initiator element (Inr) at the start of transcription, and in 
at least some late promoters, a downstream activation site. Figure is adapted from (182). 
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1.3.3 Latency  
Following a productive infection within an epithelial surface, the virus can gain access to the 
termini of the sensory neurons that innervate the site of infection. This allows the virus to be 
transported via retrograde transport to the nerve body of these innervating neurons where it can 
establish latency. Ocular, nasal or oral infections result in the establishment of latency at the TG. 
During latency, the virus lies dormant within the sensory ganglia and no infectious virus is made.  
Our knowledge of HSV-1 latency comes largely from work done in animal models 
including rabbits and mice. The rabbit model has been used to specifically study ocular 
infections and has many advantages. Rabbit eyes are similar in size to humans and many 
stressors that induce herpetic eye disease in rabbits are similar in humans (170). However, once 
latency has been established in the TG, infected rabbits can spontaneously reactivate and shed 
HSV-1 ocularly making the rabbit an unreliable model to study true latency in the absence of 
infectious virus (8, 55). Thus the mouse model is preferred to study HSV-1 latency as mice can 
be infected via many surfaces including the eye, skin, snout and footpad. Mice maintain latent 
virus in their sensory ganglia for indefinite periods of time and only very rarely does 
spontaneous reactivation lead to shedding of infectious virus (45, 99). Studies using the mouse 
model have significantly increased our understanding the factors that are responsible for and 
control viral latency. 
Following an ocular infection of murine corneas, virus can access the nerve termini of the 
neurons that innervate the cornea. The virus can travel by retrograde axonal transport to the 
neuron body of these sensory neurons where it can be detected in the TG within 2 d.p.i (73). 
Viral proteins of all gene classes are expressed and there is some transient accumulation of IE 
and E transcripts before establishment of latency (44). HSV-1 and HSV-1 preferentially establish 
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latency in different neuronal subtypes. HSV-1 (100).  While HSV-1 can infect both A5 and 
KH10 subtypes of neurons, latency occurs predominantly in A5 type neurons. It is thought that 
following infection, HSV-1 latency is immediately established within A5 fibers while infected 
KH10 fibers may become subject to death following infection. Upon the establishment of 
latency, viral gene expression is largely silenced with the exception of one set of transcripts that 
continues to be expressed and accumulate, known as the latency associated transcripts (LATs). 
The LATs are untranslated non poly A, non capped, RNA transcripts that are found abundantly 
in latently infected neurons in the ganglia and their expression coincides with the establishment 
of latency (73). While lytic viral replication does take place in the infected ganglia, it is not a 
necessary event preceding the establishment of latency (22, 144). LAT transcripts can be 
detected both in murine and human ganglia latently infected with HSV-1 (75, 158-159). The full 
length LAT is transcribed from the latency associated promoter (LAP) and this 8.3 kb transcript 
is spliced to form two stable 2.0 kb and 1.5 kb introns. These two LAT species accumulate to 
high abundance in the nuclei of latently infected neurons. No known protein species is encoded 
for the LAT and LAT functions are attributed to the transcripts themselves. These introns are 
directly anti-sense to one of the main HSV-1 lytic proteins, ICP0. One of the main functions of 
LAT is to enable HSV-1 to establish latency. Studies with viruses lacking LAT have been shown 
to establish latency less well compared to their wild type counterparts (169). Furthermore, LAT-
null viruses also reactivate with reduced efficiency (83). LAT gene expression is consistent with 
reduced lytic gene expression and this seems to be a mechanism by which the virus promotes its 
own latent state. LAT-null viruses have been shown to cause more severe pathology and induce 
neuronal death compared to wild type viruses. Thus the function of LAT is to prevent apoptosis 
of the latently infected neuron and to enhance the establishment of latency (126, 168).  
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During latency, the viral genome circularizes and is maintained as an episome within the 
nucleus (Fig. 1-5) (63). Episomal HSV-1 DNA is highly associated with host nucleosomes and 
histones (33). HSV-1 latency is thought to be controlled through differential chromatin 
regulation of the histones. A study has shown that that LAT promoter and enhancer show 
increased levels of acetylated histone H3 compared to the ICP0 gene, which indicates that the 
LAT promoter is associated with euchromatin and thus  maintained in an active state (77). In 
contrast, another study has shown that lytic promoters are progressively associated with 
heterochromatin and therefore in a repressed state (179). The LAT transcripts might be involved 
in promoting heterochromatin modifications on lytic promoters during the establishment of 
latency as LAT-null viruses show reduced levels of heterochromatin markers (71). CCTC-
binding protein (CTCF), a protein which binds to all known vertebrate insulators elements on 
DNA, has been shown to have binding sites around the LAT promoter (2). CTCF binding to 
LAT promoter/enhancer elements may prevent the LAT enhancer from activating ICP0 and other 
lytic genes (2, 17). Furthermore, it has recently been shown that LATs can also exert their effect 
through and micro-RNA antisense mechanism. A study demonstrated that LAT encodes several 
distinct micro-RNA species, some of which show complementarity to ICP0 and ICP4 may 
function by repressing their expression and thereby maintaining latency (173).  
1.3.4 Reactivation 
Reactivation of HSV-1 occurs when the viral genome re-enters the lytic replication cycle from an 
extended period of latency and progeny virus is assembled and released from the latently 
infected neuron (Fig 1-5B). Clinically, reactivation can be symptomatic (detection of virus in the 
periphery and visible disease) or asymptomatic (detection of virus in the periphery in the absence 
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of visible disease). On a molecular level, spontaneous reactivation can occur, defined by limited 
gene expression in the absence of a productive viral infection. When the virus reactivates, 
capsids and envelope proteins seem to traffic separately, via an anterograde motion to the nerve 
termini where progeny virus is assembled and released from the reactivating neuron (153). 
Despite advances in our knowledge in understanding the factors that contribute to viral latency, 
the exact mechanism by which the virus reactivates is still unknown  
Several stimuli have been demonstrated to induce reactivation in mice including exposure 
to UV-B, psychological stress, transient hyperthermia and treatment with chemical chromatin 
modulating compounds such as sodium butyrate or dexamethasone (24, 41, 117, 140, 177). 
These compounds either directly cause changes to the HSV-1 genome to promote transcription 
or cause dysfunction in the immune response which leads to reactivation. Physical neuronal 
injury following axotomy also results in viral reactivation (139). How transcriptional activation 
of HSV-1 genes occurs during reactivation is unknown but can take place in the absence of 
VP16, although not efficiently (167). The role of immediate early genes during the initiation of 
reactivation is also unclear. In one study, Tal-Singer and colleagues demonstrated that early gene 
transcripts could be detected before immediate early transcripts in a TG explant model (164). 
However, several other studies have demonstrated that recombinant HSV-1 lacking certain 
immediate early genes such as ICP0 or ICP4 reactivate poorly in vivo and express no other viral 
genes (49, 144). Once reactivation is initiated, DNA replication is necessary for full reactivation 
to take place as HSV-1 lacking the tk gene are unable to reactivate (22). So while IE genes may 
not be necessary to initiate reactivation, they may be needed for efficient transcription of other 
viral genes to promote amplification of reactivated virus.  In the absence of VP16, cellular 
proteins have been suggested to compensate for its function to initiate reactivation (94, 164). 
Cellular stress due to reactivation stimuli causes upegulation of several host transcription factors 
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including c-fos, c-jun, c-myc, and interferon regulatory factor-1 (IRF-1) (81, 164-165). Cellular 
stress also upregulates cytokines such as IL-6 can regulate LAT and ICP0 genes and lead to 
reactivation (76). Chromatin remodeling around the LAT region and surrounding lytic genes 
occurs in response to reactivation stimuli, allowing eurchromatin formation to enhance 
transcription. Stressors can also cause the loss of CTCF occupancy on LAT promoter elements, 
thus allowing the LAT enhancer to activate lytic proteins, resulting in reactivation (116).  
In the murine model, HSV-1 reactivation events are usually restricted to very few 
neurons within the infected ganglia (139). The rate of reactivation is directly proportional to the 
number of genomes in the latently infected ganglia (60). Spontaneous reactivation in mice is rare 
but has been shown to occur. Transcripts and proteins of multiple kinetic classes have been 
detected in latently infected ganglia including ICP4 (α), thymidine kinase (β) and gC (γ2) (39). 
This expression occurs in the TG in the apparent absence of infectious virus production (39, 74). 
However, other studies have also indicated that in very rare cases, spontaneous reactivation 
leading to infectious virus in the TG can occur in certain mice strains (99). The host immunity at 
the site of latency plays an important role in maintaining the virus in a latent state. In most cases, 
these limited gene expression profiles may represent abortive attempts by the virus to reactivate 
which are suppressed by the host immunity before the production of infectious virus. However, 
there are some cases where the host immunity fails to block viral reactivation thus allowing the 
production of infectious virus and recurrent disease. 
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Figure 1-5. Latent and reactivation stages of HSV-1 infection 
A) Infection of epithelial cells results in a productive infection whereby progeny virus can access 
the nerve termini of sensory neurons innervating the epithelial surface. The virus enters the nerve 
termini and nucleocapsids are transported to the neuronal cell body via retrograde axonal 
transport. The viral DNA is released into the nucleus and circularizes and persists in this latent 
state for an indefinite period of time. B) When the virus reactivates, newly formed nucleocapsids 
are transported in an anterograde fashion and infectious virus is released from the axon whereby 
it can now infect surrounding epithelial cells, resulting in recurrent infection and disease. Figure 
is adapted from (71). 
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1.4 IMMUNITY TO HSV-1 
1.4.1 Innate Immune control of HSV-1 
Corneal infection with HSV elicits cellular immune responses at the site of infection. Initial 
control of infection is mediated in part by type I interferons, namely IFN-α and IFN-β, produced 
by the infected tissue (97). These cytokines attract other cells such as neutrophils, macrophages, 
and natural killer (NK) cells (184).  Neutrophils produce several antiviral molecules such as 
nitric oxide (NO), tumor necrosis factor α (TNF-α), IFNs and interleukin (IL)-12 (27, 65). IL-12 
secretion is thought to activate NK cells that help control infection by producing  the type II 
interferon, IFNγ (34). Even in the face of a robust immune infiltrate in the cornea, the virus is 
still able to access the nerve termini that innervate the cornea and infect the TG. In the mouse 
ocular infection model, HSV-1 reaches the TG by retrograde transport within two days of 
infection where it begins the limited phase of replication (89, 149). Viral replication initiates the 
infiltration of macrophages and γδ T cell receptor + (γδ TCR+) cells (89, 150). The macrophages 
produce NO and TNF-α, and during the first 5 days after corneal infection of HSV-1, 
experimental depletion of macrophages, blocking NO production, or neutralizing TNF-α all 
significantly increase ganglionic viral titers ganglionic genome load, and the number of latently 
infected neurons in the TG (72). The γδ TCR+ T cells exert their effect by producing IFNγ; 
experimentally depleting these cells from mice within the first 7 days increases viral titer and 
spread (72, 143). Thus, innate immune mechanisms appear also to be involved in the reduction 
of virus from the TG during the early stages of viral infection in the TG before the adaptive 
immune response comes into play.  
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1.4.2 Adaptive Immunity to HSV-1 
The adaptive immune response follows the innate response and is not only responsible for initial 
clearance of virus from both the periphery and the ganglion but also to maintain the virus in a 
latent state.  The adaptive immune response is characterized by inflammation of infected tissue 
by CD4+ T cells, producing antiviral cytokines. CD4+ T cell knockout mice are more susceptible 
to HSV infection than wild type mice (34, 78, 98). Furthermore, early CD4+ T cell help is 
required for the generation of functional CD8+ T cells in the TG (40). CD8+ T cells also clear 
virus via cytokine and lytic granule production (31, 70, 88). The role of antibodies in limiting 
initial HSV infection remains unclear. No definitive correlation between levels of antibodies and 
their ability to limit the severity of HSV infection has been made. However, a significant 
repertoire of neutralizing and non-neutralizing antibodies are generated, particularly to surface 
viral antigens and the principal viral antigen targets of neutralizing antibodies in mice are 
glycoproteins, gB, gH and gD (14, 92, 123). 
 
1.4.2.1 CD8+ T cell control of viral latency  
 
Following ocular HSV-1 infection of mice, virus replicates in the cornea and infectious virus can 
be detected in the tear film by 1 d.p.i. The virus reaches the TG by 2 d.p.i and peak of viral 
replication is observed by 4 d.p.i after which virus titers decline till 8 d.p.i, when no infectious 
virus can be detected. A CD8+ T cell infiltrate ensues which can be observed beginning at 5 d.p.i 
(145). Initial activation and expansion of CD8+ T cells occurs in the draining lymph nodes 
(DLN). Professional antigen presenting cells (APC) such as dendritic cells (DC) pick up HSV 
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antigens in the cornea and migrate to the DLN where LN resident DC’s can cross present these 
viral antigens to naïve CD8+ T cells. Evidence from the murine HSV-1 skin infection model 
suggests that migratory DCs are able to prime naïve CD8+ T cells through cross-presentation of 
viral antigens (7). Viral proteins present within DCs are processed through the proteosomal 
pathway into short peptide fragments of approximately 8-10 amino acids in length (69, 93, 157). 
Presentation of these peptides on MHC Class I on DCs, along with proper costimulation can 
activate and expand CD8+  T cells whose TCR can specifically recognize a particular viral 
peptide (90).  
Following activation and expansion, virus-specific CD8+ T cells migrate out of the DLN 
and into the cornea (site of primary infection), the TG (site of latency) and also other organs and 
tissues. In the TG of C57bl/6 mice, CD8+ T cell numbers reach their peak at approximately 8 
d.p.i, which coincides with the establishment of viral latency. These CD8+ T cells represent the 
effector phase of the immune response in the TG. This population then undergoes a contraction 
phase during which 80-90% of the CD8+ T cells are lost from the ganglia starting at around 14 
d.p.i till 30 d.p.i. However, a significant population of these cells is still retained in the TG after 
34 d.p.i for the life of the animal (memory population) (67, 89, 150, 174). Persistent pools of 
memory CD8+ T cells are also retained in other tissue besides the TG, such as the lungs and 
spleens (146).  In the mouse, all the CD8+ T cells retained in the TG appear to be virus-specific 
(145). This retention of CD8+ T cells is also evidenced in human ganglia, where latently infected 
neurons are surrounded by CD8+ T cells (166, 175).  CD8+ T cells force viral latency following 
the innate response through of both IFNγ production and lytic granule release (70, 89). Actively 
replicating virus is eventually cleared from the ganglion, leaving only latent viral genomes. The 
persistent infiltrate of CD8+ T cells in the TG maintain HSV-1 in a latent state. Depletion of 
CD8+ T cells through direct administration of CD8 antibody in vivo or through 
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immunosuppresion of mice through psychological stress results in reactivation of latent virus as 
determined by an increase in genome copies (41). In ex vivo cultures of dissociated latently 
infected TG, CD8+ T cells can block reactivation and their depletion also leads to reactivation as 
evidenced by production of live virus (88).  
Using the C57BL/6 mouse model of HSV-1, we have gained an extensive picture on 
some of the mechanisms that CD8 T cells use to control reactivation. In this mouse strain, a 
majority of the virus-specific CD8+ T cells (gB-CD8) are specific to a single epitope (amino 
acids 498-505) on glycoprotein B (gB498-505). By using MHC Class I tetramers that bind to the 
TCR, it has been shown that gB-CD8 constitute up to 70% of the total CD8 T cell infiltrate 
within latently infected ganglia (67, 178). Classically, gB has been defined as a γ1 regulated 
gene, expressed with leaky-late kinetics. However recent studies demonstrate that gB-CD8 can 
recognize infected cell targets within 2 hrs of infection indicating that gB is made very early in 
infection and reactivation (112). gB-CD8 are able to completely block reactivation in ex vivo 
latently infected TG cultures (70)  
  CD8+ T cells employ two main effector functions to block reactivation namely IFNγ and 
lytic granules. IFNγ exerts its effect through several mechanisms which include the upregulation 
of proteins involved in antigen presentation, antiviral proteins involved in inhibiting viral 
translation and pro-apoptotic proteins (68, 142, 151, 186).  IFNγ can be detected constantly 
within a latently infected TG (15, 48) and when added alone, it is able to block reactivation in ex 
vivo cultures of latently infected TG (31, 87). More importantly, recent work suggests that IFNγ 
is able to block even after late gene (gC) expression, indicating that it can act very late in the 
reactivation process and may block assembly or viral transport down the axon (31). While mice 
lacking either IFNγ or its receptor are impaired in their initial ability to clear live virus at the site 
of infection, the virus is nevertheless driven to latency in these mice indicating that IFNγ is not 
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the only antiviral mechanism employed by CD8 T cells (11, 13, 84). CD8+ T cells contain 
preformed lytic granules composed several proteins including perforin, granulysin, Fas ligand, 
and granzymes which are cytotoxic to infected cells (5, 47, 127). Perforin is a calcium dependent 
pore forming cytolytic protein whose function is necessary for cytolytic activity of CD8+ T cells 
(64, 102, 128). Granzymes are serine proteases which can cleave both intracellular and 
extracellular substrates (10). Granzyme B is one of the most extensively studied granzyme and is 
responsible for the rapid induction of caspase-dependent apoptosis (171). Perforin and granzyme 
B are essential for CD8+ T cell mediated block of HSV-1 reactivation (70). Mice lacking in 
either perforin or granzyme B can clear an HSV-1 infection but an increased number of latent 
genomes are retained in the TG of these mice compared to their wild type counterparts. (70). 
Furthermore, gB-CD8 lacking either one of these components are impaired in their ability to 
block reactivation compared to wild type gB-CD8 (70).  The most important facet of CD8 T 
mediated control of viral reactivation is that they are able to do so without causing neuronal 
destruction (70, 88).  In an ex vivo study, when CD8+ T cells capable of blocking reactivation 
were depleted at 5 days post culture initiation, the cultures reactivated, indicating that the 
neuronal viability was maintained in the presence of CD8+ T cells. Furthermore, CD8+ T cells 
releasing lytic granules were able to induce the activation of caspases and apoptosis of infected 
fibroblasts but a similar phenomenon was not observed when CD8+ T cells were cultured along 
with infected neurons (70). Recent evidence shows that this non-cytolytic activity may be 
regulated by inhibitor molecules on the surface of neurons, thus protecting them from cytotoxic 
T-cell mediated killing (162). 
While HSV-1 latency has classically been considered to be an antigenically silent state, 
there is new evidence to show the contrary. In latently infected TG, gB-CD8 polarize their TCR 
toward the surface of neurons, forming an immunological synapse and release IFNγ and lytic 
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granules into this synapse (67, 70). The levels of MHC Class I (MHC-I) expressed by latently 
infected neurons has been difficult to quantify. MHC-I molecules can be readily detected during 
lytic replication of HSV-1, but their expression becomes undetectable once the virus establishes 
latency (124-125). However, the presence of CD8+ T cells surrounding latently infected neurons 
is highly suggestive of MHC-I expression during latency. Furthermore, as mentioned previously, 
transcripts of lytic genes can be detected within latently infected TG which may represent 
abortive attempts by the virus to reactivate. Since CD8+ T cells require very low levels epitope 
expression (as low as one MHC-I/peptide complex) to be stimulated (129, 163), low levels of 
protein expression during attempted reactivation could be sufficient to stimulate the TG-resident 
CD8+ T cells to block reactivation. Other evidence pointing to antigen exposure during latency is 
that TG-resident CD8+ T express high levels of intracellular granzyme B, a marker of activation 
(67, 145) and IFNγ can be consistently detected in latently infected tissue (67, 80).  Furthermore, 
the CD8+ T cells in the TG are less dependent on homeostatic proliferation signals compared to 
their counterparts in non-infected tissue consistent with the idea that they are persistently 
exposed to antigen in the TG (146). Taken together, these studies show that CD8+ T cells are 
able to provide immunosurveillance by recognizing low levels of antigen and are able to block 
reactivation before infectious virus production.  
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1.5 POTENTIAL VACCINES FOR HSV-1 
HSV-1 vaccine strategies have been divided into two types: prophylactic and therapeutic. 
Prophylactic vaccines are aimed at preventing initial infection and must theoretically elicit a 
sterilizing immunity through a strong antibody response so that no infection or establishment of 
latency occurs. The concept behind therapeutic vaccines is that it would augment the already 
existing immunity towards HSV and prevent reactivation. Both prophylactic and therapeutic 
vaccine designs have focused around viral glycoproteins such as gB and gD, two essential viral 
proteins. Vaccine strategies include the use of protein subunits, peptides, live virus or DNA 
vaccines.  
While a few prophylactic vaccines have been effective in preventing disease in animal 
models, the subunit and live attenuated vaccines that have made it to human clinical trials stage 
did not achieve the level of success to deem these vaccines safe and efficacious (12, 26, 50, 103, 
105, 155-156, 181, 189). Several key factors have hindered HSV-1 vaccine development. The 
first is that natural immunity itself does not prevent infection or disease. It has been well 
established that prior infection does not prevent subsequent infection or reactivation and the 
shedding or spread of reactivating virus. Thus such it seems highly unlikely that sterilizing 
immunity can be feasibly generated. Second, latency occurs quickly and does not require viral 
replication. Again, it seems highly unlikely that any vaccine will completely prevent the 
establishment of latency, although it is likely to limit the efficiency by which latency is 
established. The third factor affecting vaccination for HSV concerns vaccine safety and it is 
unlikely that a live virus vaccine will be deemed to have achieved a safety rating for widespread 
use.  
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 Seeing that sterilizing immunity through prophylaxis may be impossible to achieve, it 
may be more feasible to design therapeutic vaccines to prevent HSV-1 reactivation. The theory 
behind therapeutic vaccines is to augment the already existing immunity to HSV-1. One such 
therapeutic vaccine is already effective in preventing reactivation of another alphaherpesvirus, 
Varicella Zoster Virus (VZV), which cause shingles (121). The shingles vaccine is thought to 
provide a boost to the already existing immunity to VZV and prevent viral reactivation. Thus far, 
some HSV-1 subunit and live virus therapeutic vaccines have been tested in human trials with 
only minimal success (29, 160-161). It is possible that a more potent method of vaccine delivery 
is needed to improve the efficacy of therapeutic vaccines. Also, a further understanding of how a 
cellular immune response to HSV-1 is developed during a primary infection and boosted during 
a secondary challenge is also necessary. 
Glycoprotein B has been shown to induce a cellular immune response in both humans 
and animals (19, 67). In the C57bl/6 model, the strong CD8+ T cell response to this antigen 
makes it one that can be easily monitored in our mouse model of latency (67). Furthermore, gB 
is an essential protein that is involved in many aspects of the viral life cycle and any changes to 
the protein could potentially result in drastic changes in viral replication (52, 113, 185). 
Understanding how gB contributes to the pathogenecity of the virus could also help us design 
better and safer vaccines. For these reasons, we can use gB as a model antigen in our system both 
to understand viral replication and the development of HSV-specific CD8+ T cell responses.  
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2.0  SPECIFIC AIMS  
2.1 RATIONALE 
Latent HSV-1 infection of the TG is associated with a persistent virus-specific CD8+ T cell 
response that can block reactivation. However, despite constant immunosurveillance, HSV-1 can 
reactivate and cause recurrent disease. An understanding of how HSV-specific CD8+ T cells are 
maintained in the TG and block reactivation is needed to design an effective therapeutic vaccine 
for HSV-1. In C57BL/6 mice, half of the virus-specific CD8+ T cells are directed toward an 
immunodominant epitope on gB (gB-CD8; residues 498-405), a protein expressed early in 
infection. In the TG, gB-CD8 polarize their TCR toward latently infected neurons and express 
markers of activation, consistent with persistent exposure to viral antigen. Early expression of gB 
may be necessary for gB-CD8 to recognize their cognate antigen early during reactivation and 
thus quickly revert HSV-1 back into a latent state.  The central hypothesis of this thesis work 
is that early and periodic viral antigen expression during latency influences the gB-CD8 
response in the TG. The specific aims set forth in this thesis are designed to understand whether 
HSV-1 protein expression can be detected during latency and also how the kinetics of gB 
expression during lytic replication and reactivation influences the development and maintenance 
of gB-CD8 in the TG. Furthermore, as a vaccine strategy we intend to determine whether 
persistent overexpression of the gB498-505 epitope during latency, can induce a greater gB-CD8 
response in the TG.  
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2.2 SPECIFIC AIM 1 
To determine whether early and late lytic genes are expressed during latency in the absence 
of infectious virus. 
Hypothesis: 
The observation that gB-CD8 within the latently infected TG are persistently activated indicates 
that low level viral gB expression is recognized by these CD8+ T cells which then act to block 
reactivation before infectious virus production. In this aim we will design and construct a 
recombinant HSV-1 containing two fluorescent proteins expressed under lytic promoters. In this 
virus (RE-pgB-EGFP/pgCRFP), EGFP expression is controlled by the γ1 gB promoter and RFP 
expression is controlled by the γ2 gC promoter. This allows us to differentiate early gene 
expression from that occurring beyond DNA replication. We will use this virus to visualize 
promoter activity during latency and reactivation as well as to determine if lytic replication 
kinetics are maintained during reactivation.  
Viral antigens are expressed during abortive reactivation events in the absence of 
infectious virus during latency. 
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2.3 SPECIFIC AIM 2 
To determine the importance of the kinetics of gB expression for the development and 
maintenance of a gB-CD8 response in the TG and for the ability of gB-CD8 to block 
reactivation. 
Hypothesis: 
During lytic viral infection, gB is expressed as γ1 protein and its expression is mildly sensitive to 
DNA replication inhibitors. Following infection, gB-CD8 can recognize infected cell targets 
within two hours of infection, indicating that de novo gB expression occurs fairly early in 
infection. Recognition of low level gB expression soon after initiation of reactivation may be 
responsible for maintaining high numbers of gB-CD8 in an activated state within the TG. The 
expression profile of gB may also have consequences during reactivation as early expression 
may induce a rapid CD8
+ 
T cell response to block reactivation. For this aim, will design and 
construct a recombinant HSV-1 in which gB is expressed as a γ2 protein under the control of the 
gC promoter. This eliminates low level gB expression prior to DNA replication.  We will use this 
virus to explore the importance of the appropriate kinetics of gB expression for the development 
and maintenance of gB-CD8 in the TG and their ability to block reactivation ex vivo. 
Low level gB expression during latency is necessary to maintain gB-CD8 in the TG 
and gB-CD8 T cells need to recognize their antigen early to block reactivation before DNA 
replication. 
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2.4 SPECIFIC AIM 3 
To determine whether persistent overexpression of the gB498-505 epitope during latency will 
induce a greater gB-CD8 response in the TG.  
Despite constant immunosurveillance of latently infected TG, HSV-1 is able to reactivate 
following stimuli that can cause a loss or function in TG-resident CD8+ T cells. A therapeutic 
vaccine aimed at boosting the immune response in the TG would increase virus-specific CD8+ T 
cell numbers such that even following a reactivation stimuli, there are still enough functional 
CD8+ T cells to block reactivation. To test this aim, we will design and generate recombinant 
HSV-1 in which the gB498-505 epitope is expressed as tandem repeats under various viral 
promoters. We will use these viruses to determine whether overexpression of this epitope 
generates a greater gB-CD8 response in the TG and whether they are functionally capable of 
blocking reactivation. 
Hypothesis: A larger CD8+ T cell infiltrate within the latently infected TG is necessary to block 
reactivation.  
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3.0  GENERAL MATERIALS AND METHODS 
3.1.1 Cells and viruses 
Vero cells (ATCC, Manassas, Virginia), B6WT3 cells (ATCC), gB-Vero (Vero cells stably 
transfected with a plasmid expressing gB from the native gB promoter; a kind gift of William 
Goins of the University of Pittsburgh) were grown in Dulbecco's modified Eagle's medium 
(DMEM) and primary corneal fibroblasts (PCF) were grown as previously described (37) in 
minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), Penicillin-
G (100 units/ml), Streptomycin (100 mg/ml) and Fungizone (250 mg/ml). The wild type RE 
strain of HSV-1 (HSV-1 RE) was used as the basis for all viruses. 
3.1.2 Multistep in vitro growth kinetics 
Vero or PCF cells were infected with different HSV-1 viruses at an MOI of 0.01 PFU/cell, and 
incubated as stated in each study for different times. Cells and supernatants were combined for 
harvest, and infectious virus released following three freeze–thaw cycles was detected by 
standard plaque assay on Vero cells.  
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3.1.3 Analysis of HSV-1 protein expression 
Subconfluent Vero cell monolayers were infected with the indicated viruses for each study at an 
MOI of 10 PFU/cell for 1 h at room temperature (25 °C). Infections were performed in media 
lacking or containing 150 μg/ml of cycloheximide (CHX; Sigma-Aldrich, St. Louis, MO) or 
350 μg/ml phosphonoacetic acid (PAA; Lancaster Synthesis, Pelham, NH) depending on the 
study. Following media replacement under the same conditions, the monolayers were incubated 
at 37 °C. CHX-reversal studies were performed at 6 h post-media change as previously detailed 
(58). Briefly, cells were washed three times with media lacking cycloheximide but containing 
15 μg/ml actinomycin-D (AD; Sigma-Aldrich). Cells were incubated for further 2 h in media 
with AD prior to harvesting. Infected cells incubated in media buffered PAA to block DNA 
replication, were harvested at either 12 or 24h post-infection. Cells were harvested by washing in 
ice-cold PBS and the proteins solubilized in sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS PAGE) buffer, boiled, and separated by SDS PAGE. Proteins were 
detected by staining, or were transferred to Immobilon-P membranes (Millipore, Billerica, MA) 
for immunoblot analyses. Antibodies to EGFP (Affinity Bioreagents, Golden, CO), RFP 
(Becton-Dickinson, Franklin Lakes, NJ), gB and gC (Virusys) were detected using horseradish 
peroxidase and West Dura chemiluminescent reagents (Pierce Biotechnology Inc., Rockford, IL), 
as detailed previously (36). 
3.1.4 Mice and ocular infections 
Three to five-week old female wild type C57BL/6 (Jackson Laboratories, Bar Harbor, ME) were 
anesthetized by the intraperitoneal injection of 2.0 mg of ketamine hydrochloride and 0.04 mg of 
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xylazine (Phoenix Scientific, St. Joseph, MO) in 0.2 ml of Hanks buffered salt solution 
(BioWhittaker, Walkersville, MD). Both corneas were scarified and infected topically with 
purified HSV-1 viruses. Unless otherwise indicated, the infectious dose used was at 1×105 
PFU/eye in 3 μl of RPMI (BioWhittaker). All animal studies were carried out under University 
of Pittsburgh IACUC approved protocols in AALAAC approved facilities and in accordance 
with the ethical treatment of animals, as defined by the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision research. 
3.1.5 Viral replication and spread in vivo 
Viral replication in the eye was determined in tear film samples obtained using a foam-tipped 
applicator. The foam tips were transferred to DMEM, vortexed and virus titrated on Vero cells 
by a standard plaque assay. To determine viral titers in the ganglia, TG were surgically excised at 
4, 5 or 8 days post-infection (d.p.i) from euthanized animals, homogenized using trituration and 
subjected to three freeze–thaw cycles prior to titration on Vero cells. 
3.1.6 Single-cell tissue and sample preparation  
At the indicated times after infection, mice were euthanized by exsanguination. TG and draining 
lymph nodes (DLN) were excised. TG were resuspended in DMEM containing 10% FBS and 
400 U/ml collagenase Type 1 (Sigma-Aldrich) per TG for 1 h at 37 °C. Cells were then 
dissociated into single-cell suspensions by trituration. Single-cell TG suspensions were passed 
through a 40 μm filter-cap tube (BD Pharmingen) to remove debris and stained for flow 
cytometric analysis as described below. Draining lymph nodes (DLN) were excised and 
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mechanically dispersed with the use of a nylon filter and treated with red blood cell lysis buffer 
(0.16M NH4Cl, 0.17M Tris in dH2O, pH 7.2) prior to staining. Single-cell TG or DLN 
suspensions were stained for flow cytometric analysis as described below.  
3.1.7 Flow cytometry 
Fluorochrome-conjugated Abs against CD8α (clone 53-6.7), CD45 (clone 30-F11) and IFN-γ 
(clone XMG1.2), and the proper isotype control Abs were purchased from BD Pharmingen (San 
Diego, CA). Antibodies against granzyme-B (clone GB11) and the respective isotype control 
were purchased from Caltag. PE-conjugated H-2Kb dimers (BD Pharmingen) were incubated 
with SSIEFARL peptide at 37oC overnight prior to use to identify the H-2Kb-restricted HSV-1 
gB498–505-specific CD8+ T cell population. Cells prepared for flow cytometric analysis as 
described above were washed twice with FACS buffer (1% FBS, 0.1% sodium azide in PBS) 
prior to staining. Cells were incubated for 10 minutes with FC block prior to surface staining with 
the appropriate antibodies. Cells were then fixed with 1% paraformaldehyde (PFA) and 
resuspended in FACS bufferFor intracellular stainining the BD Cytofix/Cytoperm kit with 
GolgiPlug™ was used following manufacturer’s protocol.  Briefly, following surface staining, 
cells were permeabilized with Cytofix/Cytoperm solution for 20 min on ice. Intracellular Abs 
were diluted in 1X BD Perm/Wash solution and incubated with samples for 30 min on ice. After 
labeling, suspensions were washed with 1X Perm/Wash and resuspended in FACS buffer for 
analysis by flow cytometry. Flow cytometry was performed on a BD FACSAria Cell Sorter 
using FACSDiva 4.1 or 5.0.2 software (BD Pharmingen). 
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3.1.8 Quantitative real-time PCR 
DNA from latently infected TG was extracted using the Qiagen DNAeasy™ Tissue Kit as per 
manufacturer’s instructions.  Briefly, In short, collagenase-treated TG were resuspended in 200 
μl PBS per sample, then treated with 20 μl proteinase K and 200 μl Buffer AL, mixed 
thoroughly, and incubated 10 min at 70ºC on a heating block. Samples were then treated with 
200 μl 100% EtOH and transferred to a mini-spin column and centrifuged. The columns were 
treated with Buffer AW1 and Buffer AW2, with spins between each treatment, and finally, 
samples were eluted in 100 μl Nuclease-Free H
2
O (Ambion, Austin, TX). DNA was quantitated 
using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA) using 
SoftMax Pro 4.3 software (Molecular Devices) and 100 ng DNA per sample was resuspended to 
a 1 ng/ml concentration in nuclease-free H
2
O.  
25 ng of DNA or water control was mixed in duplicate with 25 μl of TaqMan Universal 
PCR Master Mix (Roche, Branchburg, NJ) and an HSV-1 glycoprotein H (gH)-specific primer-
probe set, custom designed and synthesized by ABI Assays-by-Design service (Applied 
Biosystems, Foster City, CA). Samples (50 μl/well) were assayed in 96-well plates with an ABI 
Prism 7700 sequence detector. ABI Primer Express v1.5a software default settings were used for 
instrument control and data analysis. The gH sequences were: forward primer (5’-
GACCACCAGAAAACCCTCTTT-3’), reverse primer (5’ACGCTCTCGTCTAGATCAAAGC-
3’), and probe [5’-(FAM)TCCGGACCATTTTC(NFQ)-3’]. The HSV-1 genome contains a 
single copy of the gH gene; therefore, viral genome copy number can be determined 
quantitatively by comparing the experimental C
T 
value observed from the gH primer-probe assay 
with C
T 
values of known concentrations of gH-containing plasmid standards. 
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3.1.9 CD8+ T cell stimulation assay 
For this assay, CD8+ T cells were used directly from infected TG or purified gB498-505-specific 
CD8+ T cells were used. At 8 d.p.i, TG were excised and dissociated into single-cell suspensions 
by treatment with collagenase type I as just described. One-half TG equivalent of cells were then 
combined and with 5 × 105 B6WT3 cells 18 h following transfection with plasmids specific to 
each study. For chapter 4, 8 d.p.i. infected TG were used and the conditions represented 
transfected cells expressing EGFP (EGFP-N1), RFP (mRFP-1), glycoprotein B (pPEP98) or 
untransfected cells. For chapter 6 purified gB-CD8 were used and the conditions involved cells 
transfected with pPEP98 plasmid, EGFP-N1 or plasmids expressing gB epitope mutations from 
the CMV promoter: gB-WT, gB-L8A, gB-F5L, gB-S1L, gB-S1G, gB-S1G/L8A, gB-S1G/I3A, 
gB-L8A/R7K and gB-S1G/I3N/F5L/E4S or mock transfected. Incubation was performed in the 
presence of GolgiPlug™ (BD Biosciences). Following a 6 h stimulation at 37 °C, cells were 
fixed with 4% paraformaldehyde and surface stained using fluorochrome-conjugated antibodies 
against CD8α and CD45, as described above. The cells were then permeabilized using 
Cytofix/Cytoperm (BD) and stained for intracellular IFN-γ prior to flow cytometric analysis. 
3.1.10 Ex vivo TG cultures 
Single-cell latently infected TG suspensions were plated at one-fifth TG equivalents per well in 
48-well culture plates in 400 μl of DMEM containing 10% FBS, 10 mM HEPES buffer 
(GIBCO), 10 U/ml recombinant murine IL-2 (R and D Systems), and 50 μM 2-mercaptoethanol. 
Cultures of TG were monitored for reactivation in one or two ways depending on the study.  
Virus production was assessed by testing culture supernatant fluid for live virus by standard viral 
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plaque assays by sampling the supernatant every other day for use in a standard plaque assay to 
determine the presence of infectious virus. If a fluorescent virus was used in a study, virus 
production was monitored by observing the wells under a fluorescence microscope at low 
magnification (2X objective) for expression of EGFP and/or RFP in neurons and spread to 
surrounding fibroblasts. Scanning for fluorescence was performed at low magnification to 
minimize the amount of time the cultures were exposed to uncontrolled conditions outside of the 
37 °C, 5% CO2 incubator, and to minimize UV exposure. Each assessment was conducted every 
two days for a total of eight to ten days in culture. Data are represented as the percent of wells 
that were positive for viral reactivation. 
 In studies requiring depletion of endogenous CD8+ T cells (Chapter 5), latently infected 
TG suspensions (34 d.p.i) were depleted of endogenous CD8α T cells by antibody/complement 
mediated lysis using Low-Tox M Rabbit Complement (Cedarlane). Efficiency of depletion was 
assessed by flow cytometry. Single-cell TG suspensions were plated at one-fifth TG equivalents 
per well in 48-well culture plates in 400 µl of DMEM containing 10% FBS, 10 mM HEPES 
buffer (GIBCO), 10 U/ml recombinant murine IL-2 (R&D Systems), and 50 µM 2-
mercaptoethanol. Where indicated, cultures were supplemented with exogenous gB-CD8 at 2 x 
104 gB-CD8/well.  TG cultures were monitored for reactivation by testing culture supernatant 
fluid for live virus by standard viral plaque assays as described above. Supernatants were tested 
every two days for a total of ten days in culture. Data are represented as the percent of wells that 
were positive for viral reactivation. 
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4.0  DEVELOPMENT AND PATHOGENIC EVALUATION OF RECOMBINANT 
HERPES SIMPLEX VIRUS TYPE 1 EXPRESSING TWO FLUORESCENT REPORTER 
GENES FROM DIFFERENT LYTIC PROMOTERS. 
Srividya Ramachandran, Jared E. Knickelbein, Christina J. Ferko, Robert L. Hendricks 
and Paul R. Kinchington. 
Published in: Virology. 2008 Sep 1;378(2):254-64.  
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4.1 ABSTRACT 
To develop means to explore viral gene expression in ganglia without laborious histological 
sectioning and staining, we created a two color fluorescent recombinant HSV-1, in which 
enhanced green fluorescent protein (EGFP) and red fluorescent protein (RFP) are expressed from 
the glycoprotein B (gB) and glycoprotein C (gC) promoters respectively. We show that this virus 
retained growth and pathogenic capacity both in vitro and in vivo compared to wild type HSV-1; 
established latent infections with similar genome copy number in trigeminal ganglia (TG); 
induced a similar HSV-specific CD8+ T cell infiltrate; did not induce CD8+ T cells reactive to 
EGFP or RFP; and reactivated from latency with normal kinetics in ex vivo TG cultures. 
Fluorescent EGFP expression in plaques surrounding neurons preceded RFP expression and 
provided highly sensitive detection of reactivation and different stages of infection in ex vivo TG 
cultures. Expression of both EGFP and RFP in neurons was readily detectable in whole mounts 
of TG excised during acute infection and following invivo sodium butyrate-induced reactivation 
from latency. This virus constitutes a useful reagent for monitoring lytic viral promoter activity 
in sensory neurons in vivo and in vitro. 
 
 
 
 
 38 
4.2 INTRODUCTION 
Herpes simplex virus type-1 (HSV-1) adopts two modes of infection in humans and in 
animal models: a productive lytic infection and a latent infection in which the viral genome can 
persist for prolonged periods without virion formation. Lytic infections occur in most non-
neuronal cell types and involve the coordinated and highly regulated temporal expression of 
approximately 80 viral genes to yield progeny virus. Temporal phases of viral gene expression 
can be experimentally defined into at least four classes.  The immediate early (IE or α), genes are 
transcribed first without requiring de novo protein synthesis. The transcription of early (E or β) 
and late (L or γ) genes requires the expression of functional α proteins. Maximal β gene 
transcription rates occur prior to viral DNA replication, whereas γ gene transcription peaks only 
after DNA replication has initiated. The γ genes are sub-classified into γ1 and γ2; γ1 gene 
expression can occur prior to viral DNA synthesis, while γ2 gene expression absolutely requires 
initiation of viral DNA synthesis (58).  The γ1 genes include glycoprotein gB, an essential 
glycoprotein which is an important immunogenic target of adaptive immunity in humans and 
animal models (67, 187). However, recent reports have detected gB expression at very early 
stages of viral infection (112).   
In the well-characterized murine animal model of HSV-1 corneal infection following 
scarification, virus undergoes a short productive replication in the corneal epithelium that 
enables access of infectious virions to the termini of sensory neurons that innervate the cornea.  
Virions travel by retrograde axonal transport to the neuronal nuclei within the ophthalmic branch 
of the trigeminal ganglion (TG), where viral genomes enter a latent state. Productive infection in 
the TG is limited by innate immunity, may amplify the viral load and permit lateral spread to 
surrounding neurons (72, 101). Latency in neurons is accompanied by silencing of most lytic 
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protein expression and restriction of most transcription, except that from the non- protein-
encoding latency-associated transcripts (LATs) (30, 131, 159).  Silencing lytic gene expression is 
thought to involve epigenetic mechanisms, as the latent circular episomal viral genome  becomes 
histone-associated (33, 106). Latency enables HSV-1 to coexist with the host for prolonged 
periods with the capacity to intermittently reactivate from latency leading to cause recurrent 
disease and transmission to new host.   
The once accepted paradigm that HSV latency as an antigenically silent state that is 
ignored by the host immune system has now changed to one in which sporadic antigenic 
expression occurs, permitting immune surveillance of latently infected neurons (31).  Like many 
other herpesviruses, HSV-1 expresses a limited array of lytic proteins in the context of a latent 
infection in the murine model, even though spontaneous viral reactivation from latency occurs 
rarely if ever (99).  Both transcripts and proteins of multiple kinetic classes have been detected in 
latently infected ganglia. including infected cell protein 4 (ICP4- α), thymidine kinase (TK- β) 
and gC (γ2) (39)  Expression occurs in the TG in the apparent absence of any infectious virus 
(39, 74).  This either represents normal viral gene expression during rare aborted spontaneous 
reactivation events, or may represent isolated gene expression events outside of the accepted 
kinetics of the lytic cascade (164).  Low or intermittent lytic protein expression during latency 
correlates with the retention and maintenance of an activated HSV-specific CD8+ T cell 
population in latently infected TG in close apposition to latently infected neurons, in both mouse 
and human TG (61, 67, 166, 175).  The activated phenotype of these cells is not shared by their 
counterparts in non-infected tissue such as the lungs or spleen (61, 67, 175), further supporting 
persistent or sporadic antigen expression and presentation in the context of MHC-I in neurons.   
Several HSV-1 recombinants expressing reporter genes from viral promoters have been 
developed to detect viral lytic gene expression. These viruses have incorporated Escherichia coli 
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LacZ and firefly luciferase reporters to detect viral gene expression in situ (51, 96). Such 
reagents are also potentially useful for examining lytic gene expression during HSV-1 
reactivation from latency in situ or in ex vivo ganglionic cultures.  A significant disadvantage of 
these methods is that their detection requires substrate cofactors or extensive tissue processing.  
Moreover, the long term stability of β-galactosidase may errantly indicate persistent gene 
expression in a transcriptionally silenced environment (79). We previously employed a 
recombinant HSV-1 expressing EGFP, driven by either the ICP0 or gC promoter, to track viral 
gene expression during ocular infection and reactivation from latency in explanted TG (31). 
While providing detection of viral gene expression at the level of sensitivity of real time RT-
PCR (31), these viruses were limited to detection of activity of a single viral promoter. Here, we 
describe the construction of a novel dual fluorescent reporter HSV- 1 recombinant that permits 
simultaneous detection of gene expression from two different kinetic classes of viral promoters 
within single infected cells including neurons.  
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4.3 MATERIALS AND METHODS 
4.3.1 Construction of recombinant HSV-1 RE-pgB-EGFP/pgC-RFP.  
The recombinant virus generated for this study RE-pgB-EGFP/pgC-RFP (pgB/pgC) was derived 
on the HSV-1 RE background and is a null mutant for the non-essential gC gene. Cloning was 
based on a previously detailed plasmid that contained the gC promoter driving expression of 
EGFP, followed by part of the gC ORF (31). This contained an NheI/XbaI fragment of EGFP 
obtained from the plasmid EGFP-N1 expressed in frame with the eighth amino acid of gC, but 
which is translationally stopped before the gC ORF. A 500 bp DNA fragment of the gB promoter 
was generated by PCR amplification from HSV-1 RE DNA using primers and the proofreading 
polymerase Expand (Roche, Indianapolis, IN) to amplify sequences from immediately upstream 
of the gB initiating ATG to aposition 500 bp upstream (Forward 5′ -
GGGATCCGTCGTGCCCCCCGTCAGGTAGC-3′ and Reverse, 5′-
GGGAAGCTTTGACGAAGCGGTCGTTGGCCAGCCT-3′). The primers were designed to add 
unique HindIII and BamHI sites to the distal and proximal ends, respectively, to facilitate 
cloning into unique HindIII and BamHI sites inside the polylinker sequences immediately N-
terminal to the EGFP gene in pgC-EGFP, to give pgC-pgB-EGFP. The second fluorescent gene, 
RFP was PCR amplified using mRFP-N1 with primers that added flanking NheI sites to facilitate 
in-frame cloning into the unique NheI site downstream of the gC promoter in the pgC-pgB-
EGFP plasmid. The final plasmid, pgC-RFP/pgB-EGFP, contains the gC promoter driving 
mRFP followed by the gB promoter driving EGFP. HSV-1 RE infectious DNA was co-
transfected with SspI linearized pgC-RFP/pgB-EGFP into Vero cells, using Lipofectamine 2000 
 42 
(Invitrogen, Carlsbad, CA) as per the manufacturer's instructions. Homologous recombination 
between the flanking gC promoter and the gC coding sequences enabled insertion of the dual 
fluorescent cassette into the gC locus. Fluorescent progeny plaques were identified by 
microscopy under short-term exposure to a xenon lamp, with excitation narrowed to the peak 
range of excitation of RFP and subjected to several rounds of plaque purification until pure. The 
correct insertion of the cassette into the virus as well as genetic purity was confirmed by 
Southern blotting and by absence of expression of gC protein, using a commercial specific 
antibody to gC (Virusys, Skykesville, MD). Purified virus was obtained from Vero cells using 
OptiPrep® gradients, according to the manufacturer's instructions (Accurate Chemical and 
Scientific Corp., Westbury, NY). Purified virus was aliquoted, stored at −  80 °C and quantified 
on Vero cell monolayers. 
4.3.2 Analysis of HSV-1 RNA transcription 
Subconfluent Vero cell monolayers were infected with pgB/pgC at an MOI of 10 PFU/cell for 
1 h at room temperature (25 °C) in normal media or media containing 350 μg/ml PAA. 
Following media replacement under the same conditions, the monolayers were incubated at 
37 °C. Cells were harvested at 6, 8 and 12 h post-infection and whole cell RNA was extracted 
using the RNeasy Midi Kit (Qiagen, Valencia, CA). RNA samples containing formamide were 
run on a 1% agarose gel containing formaldehyde, and then transferred to positively charged 
nylon membrane (Genescreen, Perkin Elmer, Boston, MA). Identical blots were probed for 
EGFP using a 900 bp fragment from a NheI/BglII restriction digest of EGFP-C3 and for RFP, an 
850 bp fragment from NheI/HindIII digest of RFP. Probes were labeled using random primer 
labeling extension with the incorporation using dCTP-[α-32P] (3000 Ci/mmol: Perkin Elmer). 
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Autoradiographs exposed to be in the linear range of the film were then quantified using 
MetaMorph software. 
4.3.3 In vivo induction of reactivation 
Latently infected mice (33 d.p.i) were treated with a single intraperitoneal injection of 
1200 mg/kg of sodium butyrate in PBS (final volume, 100 μl) (117). TG for confocal imaging 
were harvested 3 days post-injection as described below. 
4.3.4 Confocal imaging of undissociated TG mounts 
Mice were euthanized on days 4, 15, 35 or 36 post-infection by cardiac perfusion, using freshly 
made fixative containing sodium m-periodate (0.001 M), lysine (0.075 M) and paraformaldehyde 
(1%) in 0.1 M Phosphate buffer. TG were excised and further incubated overnight in the same 
fixative at 4 °C in round bottom 96-well plates. Fixed TG were then squash mounted onto glass 
slides with Aqua-mount and imaged using confocal microscopy (Olympus). 
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4.4 RESULTS 
4.4.1 Development of a recombinant dual fluorescent HSV-1    
Single fluorescent reporters driven by viral promoters in HSV-1 were detailed previously 
for the study of pathogenesis (3, 31) These enabled rapid assessment of viral gene expression and 
growth, but were limited to single viral temporal classes of promoters. We were interested in 
developing viruses capable of assessing gene expression at the single-cell level. We developed a 
virus in which the expression of two temporal classes of viral promoters could be simultaneously 
assessed using two fluorescent genes (Fig. 4-1). The virus was derived using a plasmid that 
contained a DNA fragment of the sequences upstream of the gB ATG. This plasmid was placed 
in the polylinker of pEGFP-N1 to drive EGFP expression in a manner similar to that used to 
derive HSV-1 in which the ICP0 or gC promoter controlled EGFP expression (Fig. 4-1B) (31). 
The plasmid also contained the RFP gene immediately downstream of the gC promoter but 
upstream of the gB promoter (Fig. 4-1C). Recombinant virus (pgB/pgC) was derived through 
homologous recombination between the flanking gC sequences and the gC gene in the HSV-1 
RE genome to contain the insertion of the two genes in the non-essential gC gene, placing the 
RFP gene under the control of the native gC promoter at its native site and same direction (Fig. 
4-1D). The RFP gene contained eight amino acids of gC fused to its N-terminus. EGFP 
expression is directed by the inserted upstream gB promoter sequences and is translationally 
stopped before the rest of the gC ORF. Thus gC is not expressed in this virus (data not shown). 
RNAs for both fluorescent genes are in the same direction as the native gC transcript and are 
presumably terminated by the native gC polyadenylation motif downstream. While the two 
RNAs share the same polyadenylation signal, this is a common occurrence in HSV-1. The 
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recombinant virus could readily be differentiated from wild type virus using fluorescence 
microscopy, and virus was isolated using excitation filters to illuminate RFP signals to minimize 
UV-induced DNA damage. Correct insertion and disruption of the gC gene was confirmed using 
Southern blotting and western blotting for gC expression (data not shown). 
 
 
 
 
 
Figure 4-1. Construction of HSV-1 RE-pgB-EGFP/pgC-RFP virus.  
A) Representation of the pgC-EGFP construct, in which expression of EGFP is driven by the gC 
promoter (pgC), followed by the rest of the gC open reading frame (gC ORF). The ‘s’ at the end 
of EGFP denotes the stop codon. Restriction sites referred to in the text are also indicated below 
the diagram. B) The subsequent construct is shown in which the gB promoter (pgB) was inserted 
at the BamHI and HindIII sites in EGFP in order to drive EGFP expression. C) The final 
construct in which mRFP was inserted at the NheI and BamHI sites so as to be driven by the gC 
promoter. D) Representation of the recombinant virus showing the final plasmid that was 
recombined into the HSV-1 RE genome at the UL44 locus. 
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4.4.2 Analysis of HSV-1 protein and RNA transcript kinetics in vitro 
The gB promoter was chosen as it is expressed very early during infection, even though it is 
classified as a leaky-late (γ1) gene, whereas gC is a true-late (γ2) gene that requires DNA 
replication for transcription. As such, EGFP expression was expected to occur in the presence of 
DNA replication inhibitors, while RFP expression should be restricted. Comparisons of EGFP 
and RFP proteins expressed from cells infected with pgB/pgC to native gB and gC protein 
expression from HSV-1 RE are shown in Fig. 4-2A. Both EGFP and gB were expressed by 8 h 
after high multiplicity infection, whereas gC and RFP were not efficiently detected until 12 h 
post-infection. Both EGFP in the recombinant virus and gB in RE were detected in the presence 
of the DNA replication inhibitor, phosphonoacetic acid (PAA). Neither gene was expressed in 
the presence of cycloheximide (CHX) or following a cycloheximide reversal by actinomycin-D 
(95), establishing that the genes were not errantly transcribed in the absence of de novo viral 
protein synthesis. Expression of RFP and gC was blocked by PAA, cycloheximide, and after 
cycloheximide reversal, consistent with true-late gene expression. We also assessed expression 
of EGFP and RFP RNAs (Fig. 4-2B). RFP and EGFP transcripts were of the size expected for 
RNAs terminating at the polyadenylation site downstream of the gC gene, with the EGFP 
transcript being smaller, as expected from its initiation downstream of the RFP gene. While 
EGFP mRNA could be detected as soon as 6 h post-infection, RFP mRNA was barely visible at 
8 h post-infection. More importantly, levels of EGFP mRNA were detected in the presence of 
PAA, while no RFP transcripts were seen in the presence of PAA. While the exposure level of 
the northern blots shown in Fig. 4-2B was normalized to the 12 h time point, extensive 
overexposure of RFP-probed northerns did not reveal any RFP transcripts in PAA-treated 
samples. Quantification of autoradiographs exposed in the linear range of the film indicated that 
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PAA reduced the EGFP transcripts to 36% of the untreated control at 12 h, whereas PAA 
reduced RFP transcripts to 2% of the untreated control. These data would be expected for a DNA 
replication-facilitated and a DNA replication-dependent expression, respectively, and establish 
that RFP and EGFP expression are regulated differentially as predicted from their true-late and 
leaky-late promoters. 
 
Figure 4-2. Kinetics of viral protein and RNA transcript expression in vitro. 
Vero cell monolayers were infected at an MOI of 10 PFU/cell with HSV-1 RE or the pgB/pgC 
recombinant. The drug treatments (150 μg/ml cycloheximide, CHX; 15 μg/ml actinomycin-D, 
AD; 350 μg/ml phosphonoacetic acid, PAA) and the times of harvest post-infection, shown in 
hours, are detailed at the top of each figure part. A) Proteins were harvested and analyzed by 
immunoblotting for EGFP, RFP, gB, and gC expression using specific antibodies detailed in 
Materials and methods and indicated to the right of the figure. The top two blots show expression 
from the pgB/pgC dual fluorescent virus, whereas the bottom blots show a parallel infection with 
RE. Coomassie brilliant blue (CBB) staining was performed for RE to show equal loading of 
samples in individual lanes. B) RNA from pgB/pgC-infected cells was analyzed by northern blot 
using DNA probes specific to EGFP and RFP. Autoradiographs for each fluorescent gene were 
normalized at the 12 h time point to enable the relative levels of gene expression at earlier times 
and in the presence of PAA to be compared. 
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4.4.3 In vitro growth kinetics 
Replication of the recombinant virus was compared to wild type RE in a multi-step growth curve 
in Vero cells infected at MOI of 0.01. Peak titers of virus progeny were observed at 24 h post-
infection for both wild type and recombinant viruses (Fig. 4-3), and the difference in mean titers 
was not statistically significant (p > 0.05) at any time points tested. Thus, the recombinant virus 
does not appear to be growth impaired in Vero cells. 
 
Figure 4-3. Multistep viral replication kinetics. 
Monolayer cultures of Vero cells were infected at an MOI of 0.01 PFU/cell with HSV-1 RE or 
pgB/pgC. At the indicated hours post-infection (h.p.i), cells and supernatants were harvested, 
pooled, subjected to three freeze–thaw cycles and the viral titers were determined. The results are 
shown as mean numbers of PFU/culture ± standard error of the means (SEM). Viral yields were 
not significantly different (p > 0.05) at any time tested as assessed by a Student's t test, suggesting 
similar rates of replication. 
4.4.4 Viral replication and spread in mice 
Because the recombinant virus is defective in the expression of gC, and some reports have 
suggested that replication of gC-null viruses may be attenuated in mouse models (95), we 
assessed in vivo growth in infected corneas and TG of C57Bl/6 mice following topical corneal 
infection. Titers of both wild type and recombinant viruses peaked in the tear film at 1 day post-
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infection (d.p.i) and decreased over time at rates which did not differ statistically (Fig. 4-4A). 
Similarly, peak TG titers of pgB/pgC and HSV-1 RE (observed at 4 d.p.i) did not differ 
significantly (Fig. 4-4B). Both viruses were largely eradicated from the TG by 8 d.p.i (Fig. 4-
4B), although a low level of residual virus (both HSV-1 RE and pgB/pgC) could be recovered 
from some mice. These data indicate the recombinant virus exhibits normal corneal virulence 
and neurovirulence in mice. 
 
Figure 4-4. Viral titers in tear films and TG of infected mice. 
Mice were infected with HSV-1 RE or pgB/pgC at 1 × 105 PFU/eye. A) Eye swabs were obtained 
at the indicated days post-infection (d.p.i) and titered on Vero cells. The viral titers are shown as 
means ± standard error of the means (SEM). B) TG were excised, homogenized and subjected to 
three freeze–thaw cycles prior to determination of viral titers. Titers of the two viruses in eye 
swabs or TG were not significantly different (p > 0.05) at any time point as assessed by a 
Student's t test. 
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4.4.5 Viral load and CD8+ T cell infiltrates within latently infected TG 
Previous reports have established the capacity of CD8+ T cells specific for the immunodominant 
gB(498–505) epitope to inhibit HSV-1 reactivation from latency both in vivo and in ex vivo TG 
cultures of C57BL/6 mice (41, 67, 88, 120). Another recent report has demonstrated that HSV-1 
reactivation frequency in ex vivo TG cultures is determined by the load of latent virus and the 
size of the CD8+ T cell infiltrate (60) Therefore, we compared the parameters of CD8+ T cell 
infiltrate and ganglionic viral load in C57BL/6 TG harboring latent pgB/pgC to those harboring 
WT HSV-1 RE following parallel corneal infections. Quantitative real-time PCR assessment of 
viral genome copy number in the TG obtained 33–36 days after HSV-1 corneal infection with 
recombinant and WT virus was statistically identical (Fig. 4-5). Moreover, neither the size of the 
overall CD8+ T cell pool, nor the size of the HSV-specific CD8+ T cell pool varied significantly 
in TG colonized by the pgB/pgC or WT RE (Fig. 4-6). 
 
 
Figure 4-5. HSV-1 genome copy number in latently infected TG. 
TG were obtained 33–36 days after corneal infection with WT HSV-1 RE or pgB/pgC. Each data 
point represents the number of gH DNA copies per TG as determined by real-time PCR analysis 
of purified TG DNA. Data are combined from two independent experiments. The difference in 
HSV-1 genome copy number between WT HSV-1 RE and the recombinant is not significant as 
assessed by Student's t test (p ≥ 0.05). 
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Figure 4-6. Immune infiltrate in latently infected TG. 
TG were obtained 33–34 days after corneal infection with either pgB/pgC or HSV-1 RE, 
dispersed with collagenase, stained for CD45, CD8, and gB498–505 -specific T cell receptor, and 
analyzed by flow cytometry. A) Representative dot plots show separated populations of total 
CD8+ T cells (circled, left plot), and CD8+ gB498–505 H2-Kb tetramer+ (gB Tet) T cells (circled, 
right plot). B) Data are presented as the mean ± SEM of the total numbers of CD8+ T cells/TG or 
the total number of gB-specific CD8+ T cells/TG. Data are pooled from two independent 
experiments with n ≥ 8 TG for all conditions. The p values were obtained with a Student's t test 
comparing the number of cells in TG infected with WT or pgB/pgC. 
 
4.4.6 RE-pgB/pgC does not induce a CD8+ T cell response to EGFP or RFP in C57Bl/6 
mice 
EGFP expressing vectors can induce CD8+ T cell responses to EGFP in BALB/c mice (1). Such 
reactivity could alter the response of CD8+ T cells to target cells infected with recombinant 
viruses that express fluorescent proteins. Therefore, we investigated the possible immunogenicity 
of EGFP and RFP proteins expressed from pgB/pgC virus. For these studies, gB, EGFP, or RFP 
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was expressed from plasmids under the control of the CMV IE promoter in B6WT3 cells. 
Expression of transfected proteins was confirmed by western blot or fluorescence microscopy 
(data not shown). Transfected or untreated cells were used to stimulate IFN-γ production by 
CD8+ T cells within dispersed C57BL/6 TG harboring latent pgB/pgC (Fig. 4-7). Only gB-
transfected cells induced a significant IFN-γ response. Thus, pgB/pgC does not induce a CD8+ T 
cell response to EGFP or RFP that is detectable in the latently infected TG. 
 
 
 
Figure 4-7. Antigen specificity of CD8+ T cells in latently infected TG. 
TG were obtained 8 days after corneal infection with pgB/pgC, dispersed with collagenase, and 
stimulated for 6 h with syngeneic B6WT3 cells that were mock transfected or transfected with 
plasmids expressing gB, EGFP, or RFP. Cells were surface stained for CD45 and CD8, and 
stained for intracellular IFN-γ. Representative dot plots show cells that were gated on CD45 and 
analyzed for expression of CD8 and IFN-γ. The graph depicts the mean percent of IFN-γ positive 
cells (n = 2/group) and standard error of the mean for each stimulation. The IFN-γ response of gB 
stimulated CD8+ T cells is significantly (p < 0.05) different from the response of the other three 
groups as assessed by an ANOVA with Tukey's post-test. 
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4.4.7 RE-pgB/pgC reactivates normally in ex vivo TG cultures 
Fluorescent protein expression in neurons and surrounding fibroblasts has previously enabled 
rapid assessment of HSV-1 reactivation from latency in ex vivo TG cultures (31) The pgB/pgC 
virus was designed to offer the advantage of being able to distinguish expression of the γ1 gB 
promoter from expression of the γ2 gC promoter within the same cell. Examination of ex vivo 
cultures of TG latently infected with pgB/pgC at low magnification revealed fluorescent plaques 
that initially expressed only EGFP, but then expressed both EGFP and RFP by day 4 (Fig. 4-8A). 
RFP expression could be detected at earlier stages (2 days post-explant; d.p.e), but this required 
higher magnification and more intense UV exposure, and we were concerned for the effects on 
culture viability. These studies establish that the dual fluorescent virus reactivates from latency, 
and that gB and gC promoters are temporally regulated following reactivation. We then 
compared the reactivation kinetics within TG latently infected with either pgB/pgC or WT HSV-
1 RE. Dispersed cells from TG harboring recombinant or wild type latent virus were cultured, 
and reactivation was determined by sequential analysis of supernatant fluids for infectious virus 
using a standard viral plaque assay. Reactivation frequencies as determined by either spread of 
fluorescence or infectious virus in culture supernatants were nearly identical for recombinant and 
wild type viruses (Fig. 4-8B). To insure that reactivating pgB/pgC did not revert to wild type 
during latency, supernatant fluids from reactivated TG cultures were added to Vero cell 
monolayers and developing plaques were monitored with a fluorescence microscope. As 
illustrated in Fig. 4-9, gB promoter-driven EGFP fluorescence was easily detected in single or 
small foci of indicator cells by 24 h in culture, and gC promoter-driven RFP was first detected in 
Vero cells by 30 h in culture. The extended time to detect fluorescent gene expression as 
compared to the kinetic studies detailed in Fig. 4-2A reflects the requirement for sufficient 
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amounts of both proteins to accumulate to enable detection following presumably much lower 
multiplicities of infection from viral reactivation. However, all cells ultimately expressed both 
promoters, and no non-fluorescent plaques were observed, demonstrating that reversion to wild 
type virus did not occur within latently infected neurons. 
 
Figure 4-8. Detection of viral promoter activity in ex vivo TG cultures by fluorescence 
microscopy. 
TG were excised 32–47 days after corneal infection with HSV-1 RE or pgB/pgC, dispersed with 
collagenase, and cultured (0.2 TG/well) at 37 °C. A) Images of pgB/pgC-infected TG cultures 
were acquired at the indicated times following culture initiation. Magnification, 10×; BF, 
brightfield. B) At the indicated times following culture initiation, HSV-1 reactivation from 
latency was detected based on spread of fluorescence from neurons to surrounding fibroblasts 
(pgB/pgC-infected TG), and on the presence of infectious virus in culture supernatants (plaque 
assay). The mean percent of cultures exhibiting HSV-1 reactivation from latency and standard 
error of the mean is shown at each time point. Based on a survival curve analysis the reactivation 
frequency of pgB/pgC was not significantly different (p > 0.05) when assessed by fluorescence or 
plaque assay; nor was the reactivation frequency of pgB/pgC as detected by either method 
significantly different (p > 0.05) than that of HSV-1 RE as assessed by plaque assay. 
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Figure 4-9. Detection of viral promoter activity within pgB/pgC-infected Vero cells by 
fluorescence microscopy. 
Supernatant fluid from reactivated ex vivo cultures of TG infected with pgB/pgC was placed on 
monolayers of Vero cells and incubated at 37 °C. Images were acquired at the indicated times. 
Magnification, 20×; BF, brightfield; Fluor, fluorescence. 
 
4.4.8 Confocal imaging of fluorescent gene expression in TG during acute infection and 
induced reactivation 
We next used the dual fluorescent virus in whole mounts of TG tissue to image viral gene 
expression in situ. Both EGFP and RFP expression were consistently detected in whole mounts 
of TG that were excised at 4 d.p.i (Fig. 4-10B). Fluorescence was detected in both neurons and 
non-neuronal cells, and was restricted to the ophthalmic branch of the TG (not shown). The 
coexpression of EGFP and RFP indicated that lytic gene expression from both γ1 and γ2 was 
ongoing in these neurons. Fluorescence was not detected in non-infected TG (Fig. 4-10A). While 
not conducted in the same study, examination of TG whole mounts from HSV-1 RE (non-
fluorescent) infected mice did not reveal any fluorescence at acute or latent time points. We then 
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explored viral promoter expression in the TG following the induction of reactivation with 
sodium butyrate, a histone deacetylase inhibitor that has recently been shown to efficiently 
induce HSV-1 reactivation from latency (117). Within three days post-intraperitoneal injection of 
a non-lethal dose of sodium butyrate, several regions of the ganglia contained multiple neurons 
expressing both EGFP and RFP, as detected in TG whole mounts (Figs. 4.10E and F). The 
numbers of these EGFP and RFP regions varied from 1 to 5, suggesting that several neurons in 
local regions of the TG were undergoing reactivation and lytic gene expression. High 
magnification revealed punctate speckles of fluorescence that was restricted to neuronal cell 
bodies (Fig. 4-10F). In two separate studies involving 8 mice each, 100% of mice showed dual 
fluorescent protein expression. Fluorescent gene expression was never detected in the maxillary 
or mandibular branches of the TG, consistent with the presence of latent genomes being 
restricted to the ocular branch, as previously reported (67). Parallel swabbing of the ocular tear 
films at day 3 following the induction of sodium butyrate failed to reveal any virus in treated or 
untreated mice (data not shown). We did not detect any fluorescence in uninfected but sodium 
butyrate-treated mice (Fig. 4-10D) nor in latently infected untreated mice (Fig. 4-10C). While 
vehicle (phosphate buffered saline; PBS)-treated latently infected mice controls were not 
performed in this work, parallel studies have indicated that PBS injection alone does not have 
any effects on latent genome copy number (unpublished observations). Fluorescent gene 
expression is not detectable in day 15 infected TG (data not shown). As such, the dual 
fluorescence seen in latently infected sodium butyrate-treated animals suggests that viral gene 
expression of both γ1 and γ2 classes in the TG reflects reactivation from latency. Virus is not 
seen at the periphery indicating that lytic gene expression can occur without necessarily resulting 
in virus delivery to the periphery. This is consistent with recent models suggesting there is 
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immune control of reactivation and peripheral virus delivery following onset of lytic gene 
expression from the latent state. 
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Figure 4-10. Detection of in situ promoter activity in whole fixed TG tissue by confocal 
microscopy. 
TG were excised from mice at the indicated days post-infection (d.p.i), fixed and mounted onto 
glass slides prior to imaging by confocal microscopy. A and D) non-infected; B) acute infection 
(4 d.p.i); C, E, F) latent infection (> 35 d.p.i). C–F) Some of the non-infected and latently 
infected mice were treated with 1200 mg/kg sodium butyrate (109) 3 days before TG excision. F) 
Zoomed image of a single neuron showing both EGFP and RFP expressions. Magnification 60X. 
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4.5 DISCUSSION 
The advancement of fluorescence imaging equipment combined with the availability of 
genes encoding proteins that fluoresce at different wavelengths has greatly enhanced our ability 
to visualize gene expression in situ.  In previous studies, we developed single fluorescent viruses 
under the ICP0 and or gC promoters to examine acute infection in mice as well as reactivation 
from latency (31). Another group has also developed a recombinant fluorescent HSV-1 to study 
acute infection and reactivation (3). However, in this virus, EGFP is expressed from the human 
cytomegalovirus major immediate early promoter (HCMV-MIEP) and not an HSV-1 promoter. 
Here we describe the construction and characterization of a recombinant HSV-1 that expresses 
EGFP and RFP from different kinetic classes of HSV-1 promoters. To our knowledge, the use of 
recombinant HSV-1 to simultaneously visualize expression of two or more genes within a single 
cell in the context of HSV-1 promoters has not been explored. This dual fluorescent reporter 
virus demonstrated the expected kinetics of EGFP and RFP protein expression regulated by the 
native promoters for gB and gC, respectively. The virus had growth phenotypes indistinguishable 
from wild type HSV-1 RE in mice, including parameters of acute corneal growth, acute TG 
replication, establishment of and reactivation from latency. Importantly, we show that latency 
was associated with a CD8+ T cell immune infiltrate in the TG that was equivalent to that seen in 
TG latently infected with wild type virus. Further, we detected no CD8+ T cell reactivity to the 
fluorescent proteins, EGFP or RFP. The fluorescent reporters allowed rapid visualization and 
quantification of reactivation events following TG explant. We were also able to demonstrate 
multiple reactivation events in situ in ganglia of latently infected mice treated with sodium 
butyrate to induce reactivation.  
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 The use of fluorescence to identify viral reactivation in ex vivo cultures of latently 
infected TG saves both time and resources compared to using standard viral plaque assays, and it 
enables dynamic studies of reactivation events ex vivo. The impetus for this work was the 
challenging issues surrounding the dynamic analysis of the expression multiple viral genes at the 
single-cell level, especially during reactivation from latency. There are no other simple, 
reproducible and sensitive assays for such analyses. The widely used approach of in situ 
hybridization (131) and/or PCR to address RNA expression, and/or immunohistochemistry 
(IHC) to identify protein synthesis (137-138) suffer from practical and dynamic limitations.  
While ISH, PCR and IHC approaches enable identification of gene expression events at the 
single cell level, they require time-consuming visual inspection of hundreds of sections per 
ganglia at any one time point and highly specific immunological reagents to enable protein 
detection. Analyses of two proteins expressed by the same cell requires either complex staining 
schemes or serial sectioning and identification by different antibodies, followed by location of 
the same cell in subsequent sections, which can be difficult.  The dual fluorescent approach with 
a virus such as that detailed here allows expression from two viral promoters to be easily 
visualized at the single-cell level in a dynamic fashion. 
 Several reporter genes, including β-galactosidase and luciferase, have been used 
to assess gene expression during the various stages of HSV-1 latency (101). The use of β-
galactosidase has the disadvantage that its detection requires fixation and treatment with 
substrate compounds for detection. While whole organs can be analyzed, it is also a static assay.  
It has also been suggested that β-galactosidase is quite stable and can be detected for long 
periods after transcription is halted in the TG, possibly leading to the errant conclusion that 
transcription is ongoing (101). Following corneal infection with our recombinant virus, 
expression of EGFP and RFP drastically decreased from four to eight d.p.i.  The rapid loss of 
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EGFP and RFP detection renders these reporters more accurate for detection of ongoing viral 
gene expression.  
 Use of luciferase in conjunction with image visualization and infrared 
spectroscopy (IVIS) system has enabled dynamic parameters of infection to be addressed, but 
this technology has not yet enabled activity to be correlated at the single-cell level. The pgB/pgC 
virus enabled easy and dynamic examination of viral gene expression in single-cell suspensions 
of dissociated TG in ex vivo cultures. The dual fluorescence is an extension of our previous 
studies in which single fluorescent viruses were used to show that IFN-γ, a CD8+ T cell effector 
molecule, can block HSV-1 reactivation.  IFN-γ inhibited reactivation in part by blocking 
expression of the ICP0 α gene, which is required for efficient reactivation of HSV-1 from latency 
(49), and also by blocking a late step following expression of the gC γ2 gene (31). However, 
these studies required infecting different mice with the different recombinant viruses.  The virus 
described herein permits such an analysis examining expression of two different temporally 
regulated genes within single neurons of the same ganglia from the same infected mouse.  HSV-
specific CD8+ T cells were shown to block HSV-1 reactivation prior to expression of gC (88).   
This virus will allow a more definitive investigation of the step in the viral life cycle at which 
CD8+ T cells block reactivation from latency in neurons. 
The pgB/pgC virus is an extremely valuable tool in studying various aspects of HSV-1 
latency and reactivation as the fluorescent proteins are expressed from different HSV-1 
promoters. This virus has applications in molecular virology and viral immunology and may lead 
to a better understanding of HSV-1 latency and reactivation both in vivo and in ex vivo 
experiments. 
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5.0  DELAYING THE EXPRESSION OF HERPES SIMPLEX VIRUS TYPE 1 
GLYCOPROTEIN B TO A TRUE LATE GENE ALTERS NEUROVIRULENCE AND 
INHIBITS THE gB-CD8+ T CELL RESPONSE IN THE TRIGEMINAL GANGLION. 
 
 
Srividya Ramachandran, Katherine A. Davoli, Michael B. Yee, Robert L. Hendricks and 
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Submitted to Journal of Virology. 
 
 
 
 
 
 
 
 
 
 
 
 63 
5.1 ABSTRACT 
Following an HSV-1 ocular infection of C57BL/6 mice, activated CD8+ T cells specific 
for an immunodominant epitope on HSV-1 glycoprotein B (gB-CD8) establish a stable memory 
population in HSV-1 latently infected trigeminal ganglia (TG) whereas non-HSV-specific CD8+ 
T cells are lost over time.  The retention and activation of gB-CD8 appears to be influenced by 
persistent viral antigenic exposure within the latently infected TG.  We hypothesized that the low 
level expression of gB from its native promoter before viral DNA synthesis is critical for the 
retention and activation of gB-CD8 in the TG during HSV-1 latency, and for their ability to 
block HSV-1 reactivation from latency.  To test this, we created a recombinant HSV-1 in which 
gB is expressed only after viral DNA synthesis from the true late gC promoter (gCp-gB). Despite 
minor growth differences compared to its rescuant in infected corneas, gCp-gB was significantly 
growth impaired in the TG and produced a reduced latent genome load. The gCp-gB and 
rescuant infected mice mounted a similar gB-CD8 effector response, but the size and activation 
phenotype of the memory gB-CD8 was diminished in gCp-gB latently infected TG, suggesting 
that stimulation of gB-CD8 requires gB expression before viral DNA synthesis.  Surprisingly, 
late gB expression did not compromise the capacity of gB-CD8 to inhibit HSV-1 reactivation 
from latency in ex vivo TG cultures, suggesting that gB-CD8 can block HSV-1 reactivation at a 
very late stage in the viral life cycle. This data has implications toward designing better 
immuogens for vaccines to prevent HSV-1 reactivation. 
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5.2 INTRODUCTION 
Herpes simplex virus type 1 (HSV-1) is a ubiquitous human pathogen that is responsible for 
repeated corneal infections that can induce a blinding keratitis.  The murine model of ocular 
HSV-1 infection has elucidated the role of the host immunity in the establishment and 
maintenance of viral latency in trigeminal ganglia (TG). HSV-1 infection of a scarified mouse 
cornea leads to a short lived and self resolving epithelial lesion caused by viral replication in and 
destruction of corneal epithelial cells.  During replication, viral genes are expressed in tightly 
regulated temporal cascade characterized by sequential expression of immediate early (α) genes 
and early (β) genes before viral DNA synthesis. The late γ genes are maximally expressed after 
viral DNA replication and can be subdivided into γ1 genes, that are expressed in low amounts 
before viral DNA replication and γ2 genes that are absolutely dependent on DNA replication for 
expression (57).  The γ1 gene product glycoprotein B (gB), a multifunctional structural 
glycoprotein, contains an immunodominant epitope (gB498-505) that is recognized by a majority of 
CD8+ T cells (gB-CD8) in C57BL/6 mice within 2 hours of target cell infection (67, 112, 178).    
Replicating HSV-1 in the corneal epithelium accesses the termini of interdigitating 
sensory neurons and travels via retrograde axonal transport to the neuronal soma in the TG.  The 
viral genome is maintained in sensory neurons in a latent state in which no infectious virus is 
produced. Latency is characterized by repression of most viral lytic cycle genes, and abundant 
expression of viral RNAs known as latency associated transcripts (LATs) with no known protein 
products (73, 75). Repression of viral protein synthesis during latency has led to the prevalent 
view of latency as a quiescent and antigenically silent infection that is ignored by host immunity. 
However, very low levels of gene transcripts and proteins from all kinetic classes have been 
detected in latently infected murine TG  (39, 74). Furthermore, the findings of recent 
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immunologic studies of HSV-1 latency in mice are inconsistent with the notion that latent virus 
is ignored by the host immune system.  CD8+ T cells infiltrate the TG during acute HSV-1 
infection, with peak accumulation occurring coincident with elimination of replicating virus and 
establishment of latency (67, 178).  In C57BL/6 mice gB-CD8 represent about half of the CD8+ 
T cell infiltrate in the TG (67).  Most if not all of the remaining CD8+ T cells in infected TG 
appear to recognize as yet undefined HSV-1 proteins (145).  The effector CD8+ T cell population 
in acutely infected TG undergoes contraction as latency is established, giving rise to a small but 
stable memory population with the same 50:50 ratio of gB-specific to gB non-specific cells (67).   
In both mice and humans, CD8+ T cells are found in the HSV-1 latently infected TG in 
direct apposition to neurons (67, 70, 166).  Taking advantage of tetramers that bind to the T cell 
receptor of gB-CD8, we have demonstrated that these cells form an immunologic synapse with 
neurons in latently infected TG, and even release lytic granules into the synapse.  Thus, CD8+ T 
cells can detect and respond to latent virus during immunesurveillance (67, 70).  The TG-resident 
gB-CD8 population exhibits a more activated phenotype (CD69 and granzyme B expression) and 
is less dependent on homeostatic proliferation signals than its counterparts in non-infected tissue, 
such as the lungs and spleen (145).  These data are consistent with persistent antigenic exposure 
within the latently infected TG. gB-CD8 can employ the cytokine interferon gamma (IFN-γ) and 
lytic granules to prevent HSV-1 reactivation from latency in vivo and in ex vivo TG cultures 
without inducing neuronal apoptosis (31, 70).  
The importance of appropriate kinetic expression of HSV-1 genes for virulence and the 
generation of host immunity has not been explored.  Here we constructed a recombinant HSV-1 
that expresses the γ1 gB gene as a γ2 gene, eliminating low level expression prior to viral DNA 
synthesis. We investigated whether this kinetic change of gB expression would influence HSV-1 
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virulence, the generation and homing of gB-CD8 to the TG, and the ability of gB-CD8 to inhibit 
the reactivation from latency.  
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5.3 MATERIALS AND METHODS  
5.3.1 Construction of recombinant HSV-1. 
The recombinant virus containing gB under the late glycoprotein C (gC) promoter (HSV-1 gCp-
gB) in the HSV-1 RE background, and its corresponding rescuant (HSV-Rescue), were 
constructed as shown in Figure 5-1. The sequence of gB and its promoter were PCR amplified 
from 54817 to 56640 bp in two sections; gB was amplified using primers gB-E (HindIII) 5’ 
 5’ 
; 
gB-S (BamHI)  
5’ 
; and the promoter was amplified using 28-E (NheI/BamHI)  
28-S (EcoRI ) 5’-GAGAATTCTGACGAAGCGGTCGTTGGCCAGCC. 
 and  
All DNAs were amplified from the RE genomic template using the proofreading 
polymerase Expand (Roche) under hot start conditions and in reactions containing 5% DMSO.  
Each PCR fragment was cut with the terminal engineered restriction sites, and triple ligated into 
the vector pUC19 as a HindIII-BamHI-EcoRI fragment to generate plasmid pK1968 which 
contained a unique BamHI and NheI site just upstream of the gB ATG start codon.  A portion 
(508 bp) of the region immediately upstream of the gC initiating ATG (96,227-95,820) 
containing the gC promoter (104) was similarly PCR amplified using the primers gCp-S 
(BamHI) 5’  and gCp-B (Nhe-Bgl2-AflII) 5’ .  Restriction sites in the primers are underlined.  
The PCR product was then cut with BamHI and NheI, inserted into the corresponding sites 
engineered upstream of gB in pK1968.  The resulting construct was digested with NheI and AflII 
and an NheI-AflII fragment of pEGFP-C1 containing EGFP and its polyadenylation signal were 
inserted to be upstream of the gC promoter and downstream of, and driven by the gB promoter. 
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Plasmid derivative for the rescuant was developed by PCR amplifying a portion of the gB gene 
and the promoter/UL28 region using the primers 54810F -EcoRI 5’ 
HSV-gCp-gB was derived by co-transfection of infectious wild type HSV-1 RE viral 
DNA with plasmids linearized with SspI into Vero cells, using the Lipofectamine 2000 reagent 
(Invitrogen, Carlsbad, USA). GFP positive virus plaques were picked and plaque purified to 
homogeneity, as detailed previously (Chapter 4).  The rescuant (HSV-Rescue) was derived by 
co-transfecting viral DNA from the EGFP positive gCp-gB virus with the promoter-gB plasmid 
containing the novel AvrII site. Rescuant plaques were selected and picked based on loss of 
fluorescence followed by subsequent titration of the mixed progeny from the transfection. (Fig. 
5-1 i-iii). The recombinants were positively identified for inserted DNA sequences (gCp-gB) or 
for the inserted AvrII site (Rescue) by Southern blot analysis of restricted viral DNA. Viral DNA 
from both viruses were cut with NcoI, AvrII and NcoI - AvrII double digests, and probed with 5’ 
32P-radiolabelled oligonucleotides derived from the gB coding sequence or the UL28 coding 
sequence (Data not shown).            
 AND and 55812R AvrII-5’   
GTCCTCCAGCACCTCGCCCCTAGGCTACCTGACG: and 55812F AvrII-5’  
GTCAGGTAGCCTAGGGGCGAGGTGGAGGAC with 56801R  HindIII 
GCCCAAGCTTACGACGGGGACCGTGTCGCCGT (mutations in bold and underlined).  Each 
PCR fragment was digested with the terminal end restriction sites, combined and triple ligated 
into EcoRI and HindIII digested pUC19.   The single mutation resulted in the insertion of a silent 
non-coding unique AvrII restriction site. All DNA inserts were sequenced for integrity. 
 A recombinant with Us3 deleted in the HSV-1 RE background was also derived 
for this study (Fig. 5-1 iv). Sequences of part of the US3 protein were PCR amplified from the 
HSV-1 RE genomic template using the GC-RICH PCR System (Roche) under hot start 
conditions and primers US3.5F 5' - GGG AAT TCA TGT ACG GAA ACC AGG ACT AC - 3' 
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and US3.5R 5' - GGA AGA TCT TCA TTT CTG TTG AAA CAG CGG CAA - 3'. The PCR 
product was digested with BglII and EcoRI and ligated to pEGFP-C2 digested with BamHI and 
EcoRI. Collapse of this construct with Xho I resulted in removal of the N terminal part of the 
US3 coding sequence encoding residues 1 to 169. The remaining part lacks ATG, is out of frame 
with respect to EGFP and lacks domains required for kinase activity. DNA containing the 
promoter sequence upstream of the US3 gene was PCR amplified using US3PF primer 5' - GCG 
CCC TAG GGC TAG CTC GCC GCA CCG TGA GTG CCA - 3' and US3PR primer 5' - GCC 
ATT AAT ATT AAT GCC GCG AAC GGC GAT CAG AGG GTC AGT - 3'. This PCR 
product was digested with inserted to replace the CMV IE promoter. The resulting construct 
contained EGFP flanked by US3 promoter and the distal end of US3 (Fig. 5-1 iv). Viruses were 
selected from co-transfections of HSV-1 RE viral DNA with the linearized plasmid and were 
identified and plaque purified based on gain of EGFP fluorescence. Insertion of GFP and 
deletion of the N-terminus of the US3 coding sequences was confirmed by Southern blot analysis 
of viral DNA (data not shown). 
5.3.2 Analysis of eIF2α phosphorylation in primary corneal fibroblasts 
Confluent primary corneal fibroblasts (PCF) were infected at an MOI of 5 with either 
Rescue or gCp-gB for 1 hour at 25oC either in the presence or absence of PAA (350 µg/ml). 
Media was replaced following 1 hr under the same conditions and cells were incubated at 37oC 
for 4, 8 or 12 hours. Thirty minutes prior to harvest, cells were incubated with 5µM of 
Thapsigargin (Tg). Cells were then washed and the proteins were solubilized in SDS PAGE 
buffer, boiled, and separated by SDS PAGE. Immunoblot analysis was then performed using 
antibodies to eIF2α (Abcam), phosphorylated eIF2α (phospho-S51;Abcam) and gB. 
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5.4 RESULTS 
5.4.1 Construction and characterization of recombinant HSV-1. 
We created HSV-1 gCp-gB that exhibits gB expression with true-late kinetics and complete 
dependence on viral DNA replication.  Construction of the virus and its recscuant (Rescue) are 
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depicted in Figure 5-1. In place of its native promoter, gB is driven by a γ2 gC promoter in gCp-
gB so that the protein is only expressed following DNA replication. The strategy required 
maintenance of the gB promoter in the genome, because it is contiguous with the upstream UL28 
essential ORF encoding a terminase subunit. As such, HSV-1 gCp-gB was engineered so the gB 
promoter drove expression of EGFP followed by a polyadenylation motif to terminate RNA 
made from the gB promoter (Fig. 5-1 ii). The rescuant (Rescue) engineered on the gCp-gB 
background restored gB expression back to its native promoter and could be differentiated from 
parental virus (HSV-1 RE) by the insertion of a silent and novel AvrII restriction site (Fig. 5-1 
iii). 
An immunoblot analysis performed at 8 hours post infection (h.p.i.) revealed abundant 
expression of gB in cells infected with wild-type HSV-1 RE (WT RE) and Rescue virus, but only 
trace expression in cells infected with gCp-gB virus (Fig. 5-2A). This was similar to the low 
levels of gC protein expressed by all the viruses (Fig. 5-2B). By 12 h.p.i similar levels of gB 
expression were detected in WT RE, Rescue, and gCp-gB. As expected, the presence of the 
HSV-1 DNA replication inhibitor phosphonoacetic acid (PAA) blocked expression of gC in all 
viruses and of gB protein in gCp-gB (Fig. 5-2A and B, lane 6), while permitting low level 
expression of gB from its native promoter in WT RE and the Rescue virus (Fig. 5-2A lane 6).  
These data confirm that gB expression kinetics in gCp-gB is regulated as a γ2 late gene, 
eliminating the low level gB protein expression prior to DNA replication observed when 
expression is regulated by its native promoter.   
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Figure 5-1.  Construction of HSV-gCp-gB, HSV-Rescue and HSV-1 Us3KO viruses. 
 
i) Representation of the HSV-1 genome showing the UL27/UL28 locus which contains the gB 
promoter (arrow) in the UL28 coding sequences upstream of the gB ORF. The restriction sites 
were used to identify the insertion, as detailed in the text, are indicated on the gene locus at their 
approximate positions. ii) Expansion of the corresponding region in recombinant HSV-1 gCp-gB 
virus, showing that in place of its native promoter, gB is driven by the well characterized γ2 gC 
promoter in gCp-gB so that the protein is only expressed following DNA replication. The strategy 
required maintenance of the gB promoter in the genome, because it is concurrent with the 
upstream UL28 ORF encoding an essential terminase subunit. As such, HSV-1 gCp-gB had the 
gB promoter driving EGFP followed by a polyadenylation motif to terminate RNA made from the 
gB promoter. iii) Representative structure of the HSV-Rescue virus, showing that gB expression 
is restored to its native promoter, but that a unique non coding AvrII site distinguishes it from the 
parental strain. iv) Representation of the genome showing the position of the US3 locus, which 
was modified such that the US3 promoter drives the expression of EGFP, followed by an 
untranslated and nonfunctional portion (amino acids 170-481) of US3 ORF.  
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Figure 5-2.  HSV-gCp-gB expresses gB with true-late kinetics.  
Confluent monolayers of Vero cells were infected with HSV-1 RE, gCp-gB or Rescuant at an 
MOI of 10 with or without the addition of 350μg of phosphonoacetic acid (PAA). Total SDS 
PAGE separated proteins were analyzed by immunoblotting for gB (A) or gC (B) using pools of 
monoclonal antibodies. The times of harvest are shown above each figure and lane designation in 
hours (h). The top panel of each figure represents infection with HSV-1 RE, the middle panel is 
HSV-Rescue and the bottom panel is HSV-gCp-gB. Only the region corresponding to the main 
glycoprotein products are shown.   
 
5.4.2 Viral replication of gCp-gB is impaired in vivo but not in culture. 
Following infection of Vero cell monolayers at a low multiplicity of infection (MOI = 0.01 
PFU/cell), gCp-gB exhibited a growth curve that was nearly identical to those of the rescuant 
(Rescue), demonstrating normal replication efficiency for gCp-gB in vitro (Fig. 5-3A). However, 
gCp-gB virus showed some growth impairment in vivo in mice.  Following corneal infection of 
C57BL/6 mice, we observed a significant (approximate 2-fold) decrease in tear film titer for 
gCP-gB compared to its rescuant at 1 day post infection (d.p.i.) (Fig. 5-3B), but titers equalized 
thereafter. By 7 d.p.i., infectious virus could not be detected in the tear film of mice infected with 
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either virus demonstrating that gCp-gB virus is cleared with normal kinetics in the cornea. We 
next assessed acute viral replication in the TG. Replication of gCp-gB was severely impaired (5-
fold) at 4 d.p.i. (peak of virus replication) compared to the rescue virus (Fig. 5-3C) and wild type 
virus (not shown). Infectious gCp-gB and its rescuant were cleared from the TG by 8 d.p.i. Thus, 
HSV-1 virulence is compromised in the cornea and more profoundly in the TG when gB 
expression prior to viral DNA replication is prevented.   
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Figure 5-3. Viral replication titers are reduced in corneal tear films and TG of gCp-gB 
infected mice but not in culture.  
 
A) Vero cell monolayers were infected at an MOI of 0.01 with gCp-gB or Rescue viruses. Cells 
and supernatants were collected at the designated hour post infection (hpi), subjected to three 
freeze-thaw cycles and plaque forming units (PFU)/ml of HSV-1 were measured on Vero cells. 
The difference between the viral titers of gCp-gB and Rescue was not significantly different at 
any time tested (p>0.01).  The experiment was repeated two independent times with similar 
results. B&C) Mice were infected with Rescue or gCp-gB at 1 x 105 PFU/eye. B) Eye swabs 
were performed at the indicated days post infection (d.p.i.) and HSV-1 was titered on Vero cells. 
The viral titers are shown as means ± standard error of the means (SEM). *Titers were 
significantly different as assessed by a Students’ t-test (p<0.05)  C) Infected TG were excised, 
homogenized and subjected to three freeze–thaw cycles and HSV-1 titered on Vero cells. Each 
data point represents the mean viral titer from a single TG as determined by plaque assay. The 
data are combined from two independent experiments.  The significance of differences in TG 
titers was assessed by a Student's t-test (*** p = 0.0008), (* p= 0.0573). At 8 d.p.i., no infectious 
virus could be detected from TG infected with either virus.  
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5.4.3 Establishment of HSV-1 gCp-gB latency is impaired.  
Previous studies have demonstrated that replication-impaired HSV-1 viruses establish 
latency with reduced efficiency as determined by genome copy load per ganglia (59). Since 
replication of gCp-gB was impaired in the TG, we wanted to test whether it was also impaired in 
its ability to yield latent genome loads equivalent to its rescuant. Corneal infection of mice with 
1 x 105 PFU/eye with gCp-gB indeed resulted in a reduced latent viral load in the TG compared 
to its rescuant when assessed at 14, 34, and 64 d.p.i. (Fig. 5-4).  However we were able to 
equalize the latent load of gCp-gB and its rescuant by reducing, three-fold, the infectious dose of 
the Rescue virus (Fig. 5-4).   
 
 
Figure 5-4.  HSV-gCp-gB establishes latency with fewer genome copies compared to the 
Rescue. 
Corneas of mice were infected at an infectious dose of 1x105 or 3x104 PFU/eye.  TG were excised 
at 14, 34 and 64 days post infection (d.p.i.) and genome copies were determined by real time 
PCR. Each data point represents the viral genome copy from a single TG. The data are combined 
from two independent experiments. At a similar infectious dose (1x105) the rescue virus induced 
a significantly higher (p<0.05) latent viral load than the gCp-gB virus at all times tested.  
Reducing the infectious dose of rescue virus 3-fold relative to that of gCp-gB resulted in latent 
viral loads that were not significantly different (p>0.05).  Data were analyzed by a Student’s t-
test. 
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5.4.4 Delayed onset of gB expression does not influence the initial expansion of gB-CD8 in 
the lymph nodes, but does reduce their accumulation and retention in the infected TG. 
We next asked whether the altered kinetics of expression of gB would influence the 
initial expansion of gB-CD8 in the draining lymph nodes following corneal infection.  At 8 d.p.i 
a similar total number (Fig. 5-5 A left) and frequency of gB-CD8 (Fig. 5-5A right) were 
observed in lymph nodes of mice infected with gCp-gB and rescuant, indicating that delayed gB 
expression did not impair priming of naïve CD8+ T cells. Concordant with lower replication 
levels of gCp-gB in the TG, the total numbers of CD8+ T cells infiltrating gCp-gB and rescuant 
infected TG were significantly reduced at all time points observed (Fig 5-5B left panel). Analysis 
of the gB-CD8 population in the TG revealed the expected expansion (8 d.p.i.), contraction (14-
30 d.p.i.) and stable memory population (>30 d.p.i) with both gCp-gB and rescue virus (Fig. 5-
5B right panel).  However, the gB-CD8 effector population was diminished in gCp-gB acutely 
infected TG at 8 d.p.i. and 14 d.p.i (Fig. 5-5B right panel) and while both viruses established a 
stable gB-CD8 memory population by 34 d.p.i., the frequency of these cells was significantly 
reduced in gCp-gB (18%) infected TG compared to its rescuant (49%) (Fig 5-5B right panel).   
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Figure 5-5. HSV-gCp-gB infected mice contain fewer gB-CD8 in their TG but not lymph 
nodes. 
 
TG or lymph nodes were excised and dispersed into single cell suspensions and stained for CD45, 
CD8, gB498-505-T cell receptor or intracellular granzyme-B expression, and analyzed by flow 
cytometry. The data are represented as the mean +/- SEM of the mean. A) The graph represents 
the total number of CD8+ T cells (left) and the percentage of gB-CD8+ T cells (right) in draining 
lymph nodes of mice infected with 1 x 105 PFU/eye of either Rescue or gCp-gB at 8 d.p.i. The 
data are combined from two independent experiments. The mean numbers of total CD8+ T cells 
and the  percentages of gB-CD8 between Rescue and gCp-gB is not significantly different as 
assessed by Students’ t-test (p>0.05). B) The left panel represents the total number of CD8+ T 
cells and the right panel represents the percentage gB-CD8+ T cells per TG from mice infected 
with 1 x 105 PFU/eye HSV. The mean for the percentage of gB-CD8+ T cells is shown within 
each bar graph. The data are combined from three independent experiments. The mean 
percentages of total and gB498-505-specific CD8 T cells between Rescue and gCp-gB is 
significantly different at all time points tested as assessed by Students’ t-test (p<0.05). 
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5.4.5 gCp-gB fails to activate gB-CD8 during latency. 
Non-HSV-specific CD8+ T cells (OT-1) are gradually lost from the latently infected TG 
over time, while a stable population of HSV-specific CD8+ T cells is maintained, suggesting that 
antigenic exposure is required to maintain the TG resident CD8+ T cell population (145).  
Therefore, we hypothesized that the low frequency of gB- CD8+ T cells in gCp-gB infected TG 
during latency might reflect reduced antigenic exposure.  We assessed gB-CD8 activation based 
on intracellular granzyme B expression in TG harboring equal ganglionic loads of gCp-gB and 
rescuant virus.  We measured the absolute number (Fig. 5-6 left) and frequency (Fig. 5-6 right) 
of granzyme B positive gB-CD8 during the acute phase at 8 d.p.i, when there is high level of 
antigen and during latency at 34 d.p.i where antigenic exposure is minimal. While the absolute 
number of gB-CD8 at 8 d.p.i was significantly different between gCp-gB and Rescue, the 
frequency of gB-CD8 retained in the TG for each infection were almost equal (although 
significantly different). However at 34 d.p.i, the frequency of gB-CD8 was greatly reduced in 
gCp-gB infected TG, consistent with reduced antigenic exposure. 
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Figure 5-6. Fewer gB-CD8 in the TG of gCp-gB mice are activated during latency.  
The graphs represent the absolute number of gB-CD8+ T cells (left) and percentage of gB-CD8 
(right) in infected TG expressing intracellular granzyme-B at 8 or 34 d.p.i. from mice infected 
with 3 x 104 PFU/eye Rescue and 1 x 105 PFU/eye gCp-gB to yield equal genome loads. The data 
are combined from two independent experiments. The differences between the absolute numbers 
and percentages are significantly different at all time points as assessed by a Students’ t-test (p < 
0.01). 
 
5.4.6 The diminished gB-CD8 population in gCp-gB latently infected TG is not due to 
growth impairment.  
To determine if the altered gB-CD8 frequency in gCp-gB infected TG during latency 
resulted from impaired virus replication during acute infection we compared the absolute number 
and frequency of gB-CD8 in TG that were latently infected with gCp-gB or a second 
recombinant HSV-1 in which replication was similarly impaired by disruption of the US3 kinase 
gene (US3KO; Fig. 5-1 iv).  In US3KO, gB is expressed from its native promoter and thus made 
at low levels prior to viral DNA synthesis. The US3KO and gCp-gB viruses induce a similar load 
of latent virus in the TG at 34 d.p.i. (Fig. 5-7A), but the TG harboring latent US3KO virus 
exhibited a significantly larger population of gB-CD8 (Fig. 5-7B), indicating that late gB 
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expression, rather than a low copy number, leads to the reduced frequency of gB-CD8 in TG 
harboring latent gCp-gB.   
 
 
Figure 5-7. Delaying gB contributes to the diminished gB-CD8 response in the TG.  
 
Mice were infected at 1 x 105 PFU/eye with gCp-gB or another replication impaired HSV-1 
lacking the US3 kinase (US3KO). The data shown are combined from two independent 
experiments. A) Viral genome copies were determined by real time PCR at 34 d.p.i. The data is 
represented as the mean +/- SEM of the mean. The differences between gCp-gB and US3KO 
genome copy numbers are not significantly different as assessed by Students’ t-test (p>0.05). B) 
Single cell suspensions of TG infected for 34 days were stained for CD45, CD8 and gB498-505 
TCR expression and analyzed by flow cytometry. The data is presented as the mean +/- SEM of 
the mean. The percentage of gB498-505-specific CD8 T cells (B) is significantly different between 
Rescue and gCp-gB at all time points tested as assessed by Students’ t-test (p=0.0034).  
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5.4.7 gB-CD8 are capable of blocking reactivation of gCp-gB. 
The early expression of gB before viral DNA synthesis might provide a requisite window 
of opportunity for gB-CD8+T cells to prevent full reactivation and virion formation.  To test this 
hypothesis, cultures of dispersed TG harboring similar loads of latent gCp-gB or rescuant virus 
were depleted of endogenous CD8+ T cells, reconstituted or not with purified gB-CD8, and 
monitored for HSV-1 reactivation based on recovery of infectious virus from culture 
supernatants.  Figure 5-8A verifies that the TG cell suspensions were effectively depleted of 
endogenous CD8+ T cells.  In the absence of added gB-CD8+ T cells, reactivation was observed 
in neurons harboring both gCp-gB and the rescuant, although the reactivation frequency was 
slightly lower in neurons harboring gCp-gB (Fig. 5-8B).  Notably, late gB expression did not 
impair the ability of the gB-CD8+ T cells to block reactivation.  Thus, gB-CD8 can act very late 
in the viral life cycle to block full reactivation and formation of infectious virus. 
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Figure 5-8. gB-CD8 can block gCp-gB reactivation.  
Mice were infected with 3 x 104 PFU/eye Rescue and 1 x 105 PFU/eye gCp-gB to establish equal 
genome copies during latency. TG were excised at 34 d.p.i. and single cell suspensions were 
depleted of CD8 as described in the materials and methods section. Depleted TG were plated as 
1/5th TG cultures and half the cultures received add-back of gB498-505-specific CD8 T cells (gB-
CD8 T cells) and the other half did not. Reactivation was monitored by sampling supernatants for 
infectious virus via plaque assay. A) Representative dot plots before and after CD8 depletion, 
showing depletion efficacy. B) Representative graph showing reactivation frequency of Rescue 
and gCp-gB virus with or without gB-CD8 add-back. The experiment was repeated three 
independent times with similar results.  
 
 
5.4.8 Growth impairment in primary cells involves the eIF2α pathway.  
The impaired growth of gCpgB virus in the TG was intriguing, since the majority of gB is made 
following viral DNA replication in HSV-1 RE infected cells.  In the course of these studies, it 
was reported that gB also acted at a level to counteract the cell induced stress response involving 
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an ER-resident kinase, PERK (113). ER stress results in PERK activation by auto-
phosphorylation which subsequently phosphorylates eIF2α, a eukaryotic translation initiation 
factor required for translation.  Mulvey et al showed HSV-1 gB binds to PERK to block 
phosphorylating eIF2α. Impaired gCp-gB growth in the TG may be partly caused by the inability 
of gB to affect the PERK stress response pathway early on in the lytic cycle.  We therefore 
determined if eIF2α phosphorylation was higher in gCp-gB infected cells. For this work, a 
primary cell type derived from the cornea was used, since we rationalized that subtle differences 
in viral growth might be more apparent in cell lines closes to the natural host. When a multistep 
growth curve was assessed on primary corneal fibroblast (PCF) cells following a low mulitplicity 
infection of 0.01, we found at 24 h.p.i that gCp-gB shows a significant reduction in viral titer 
within the infected cell compared to the Rescue (Fig. 5-9A).  This is in contrast to the lack of 
growth difference observed in Vero cells (Fig. 5-3A).  We then assessed the levels of 
phosphorylated eIF2α in PCF cells infected with gCp-gB or Rescue in a single step infection..  
In each case of viral infection, thapsagargin, a chemical inducer of the ER stress response, 
induced signficantly large amounts of phosphorylated eIF2α, indicating that eIF2α could be 
potentially phosphorylated in infected cells.  In rescue virus infected cells, relatively low levels 
of eIF2α were detected at all time points. However, there was overall a detectable increase in 
eIF2α phosphorylation in gCp-gB infected cells compared to Rescue at all time points.  
Furthermore, there was a noticeable reduction of phosphorylated eIF2α at late times post 
infection in Rescue-infected cells coinciding with a peak in gB-accumulation. In gCp-gB-
infected cells, there was a more modest reduction in phosphorylated eIF2α indicating that this 
virus was impaired in its ability to overcome this axis of the stress response. In both viruses, 
when gB expression was minimized by performing infections in the presence of PAA, eIF2α 
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remained phosphorylated demonstrating that gB expression was required for the 
dephosphorylation of eIF2α (Fig. 5-9B) 
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Figure 5-9. Growth impairment of gCp-gB in primary cells is in part due to host control 
through eIF2α.  
A) Representative graph of growth curves in primary corneal fibroblasts (PCF) cells. Confluent 
cells were infected at an MOI = 0.01 with either Rescue of gCp-gB. At indicated times post 
infection cells and supernatants were harvested and infectious virus was assayed via plaque assay. 
The difference between viral titers of Rescue and gCp-gB is significantly different at 24 h.p.i 
(p<0.05). B) eIF2α phosphorylation pattern in PCF cells. Confluent cells were infected at an MOI 
= 5 with or without 350ug/ml phosphonoacetic acid (PAA). Cells were treated with 0.5uM 
thapsigargin (Tg) 30 minutes prior to harvest or left untreated. Samples were analyzed by western 
blotting for eIF2α, phosphorylated eIF2α (p-eIF2α) and gB. 
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5.5 DISCUSSION 
To our knowledge this is the first study to assess the influence of viral gene expression 
kinetics on host immunity. We employed an infection model in which latent virus influences the 
functional characteristics of the memory CD8+ T cell population (146).  The sequential 
expression of HSV-1 genes during lytic infection has been appreciated for some time, but little is 
known about the importance of expression kinetics for viral virulence or for targeting of viral 
proteins by host immunity.  Using classical molecular approaches gB was shown to be produced 
early in the viral life cycle before viral DNA replication, leading to its classification as a leaky-
late γ1 gene (122, 130).  Very low levels of protein synthesis are required to sensitize cells for 
recognition by CD8+ T cells (163). Accordingly, while gB is hardly detectable by 
immunoblotting at very early stages of infection, Carbone and colleagues showed de novo gB 
synthesis can be detected by gB-CD8 as early as 2 hours post infection (112). Moreover, gB498-
505 represents a strongly immunodominant epitope that is recognized by up to 70% of HSV-
specific CD8+ T cells in lymphoid organs of C57BL/6 mice.  Collectively, these findings suggest 
that early expression of gB might have important implications for both replication and host 
immunity.   
We observed that gCp-gB exhibited a significant loss of neurovirulence in infected mice. 
HSV-1 gB is required for HSV-1 entry into cells by mediating fusion of the viral envelope to the 
host cell membrane (52, 172). However, several recent studies have demonstrated other 
functions for gB during the viral life cycle. Importantly, gB is able to counteract the host-
mediated shut down of protein translation thus allowing viral replication to continue. gB is able 
to do this by binding to PERK, a kinase able to detect cell stress, and consequentially preventing 
the phosphorylation of eIF2α, thus allowing protein translation to continue (113). This appears to 
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be a redundant mechanism to allow viral replication to continue, since eIF2α phosphorylation is 
also reversed by γ34.5, also a γ1 gene (18, 176).  In our studies we observed some growth 
impairment of gCp-gB virus in the cornea and a more severe impairment in the TG in vivo, but a 
normal growth curve was observed when gCp-gB virus was grown in Vero cells in vitro.  This is 
in agreement with our observation of gCp-gB virus growth impairment when grown in primary 
corneal fibroblasts that was correlated with a slight increase in eIF2α phosphorylation.  Thus the 
growth impairment of gCp-gB seen in the TG of infected mice could be in part due to the virus’ 
inability to overcome the host response. Other studies have also shown that phosphorylation of 
gB is essential for the egress of nucleocapsids from the inner nuclear membrane (185). So there 
also exists the possibility that transport of gCp-gB capsids from the cornea to the nerve body is 
compromised which could also contribute to its poor growth in the TG. Our findings emphasize 
the selective importance of the kinetics of gB expression for viral growth in certain cell types.  
The mechanisms underlying the growth impairment of gCp-gB are currently under investigation.  
HSV-1 latency differs from chronic infections in that viral DNA replication does not take 
place and viral protein expression is largely silenced. However, HSV-1 latency is no longer 
considered an entirely antigenically silent state. Recognition of latent virus by CD8+ T cells was 
first suggested by the observation that activated CD8+ T cells surround infected neurons in 
murine latently infected TG, where spontaneous reactivation and virion formation was not 
observed (87). Subsequent studies confirmed this notion by demonstrating that gB-CD8 release 
lytic granules into an immunologic synapse in situ (67, 70), and that the endogenous CD8+ T 
cells in dispersed latently infected TG can block HSV-1 reactivation from latency in ex vivo TG 
cultures (67, 88).  gB-CD8 employ both IFN-γ and lytic granules to prevent HSV-1 reactivation 
in neurons with preservation of neuronal viability (31, 70).  Moreover, recent findings suggest 
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that ganglionic CD8+ T cells that are not specific for gB498-505 are nevertheless HSV-specific and 
capable of blocking HSV-1 reactivation from latency in ex vivo TG cultures (145).   
We hypothesized that detection of viral protein early in the reactivation process is 
essential for the ability of CD8+ T cells to block full HSV-1 reactivation prior to virion 
formation.  Moreover, the maintenance of a constant level of latent viral genomes in the TG over 
long periods of latency in mice (our unpublished observations) suggested that inhibition of 
reactivation likely occurs prior to viral DNA synthesis. Indeed gC transcripts are not detectable 
when latently infected TG are cultured in the presence of CD8+ T cells capable of blocking 
reactivation (88). To test these theories we created a recombinant virus (gCp-gB) that expresses 
gB as a late protein from the γ2 regulated gC promoter, thus abrogating expression of gB protein 
prior to DNA synthesis. This should not influence the level of gB expression since gB and gC are 
expressed at similar levels at late times post infection (154).  The expansion of naïve HSV-
specific CD8+ T cells in the lymphoid organs appears to result from cross-presentation of viral 
antigens rather than by direct presentation by infected antigen presenting cells (7).  Accordingly, 
any of the kinetic classes of HSV-1 proteins could theoretically be presented, and delayed 
expression of gB should not greatly influence the initial expansion of gB-CD8+ T cells in mice 
infected with gCp-gB.  This was in fact observed as quantitatively similar expansion of gB-CD8 
was observed in draining lymph nodes of mice infected with gCp-gB and rescuant virus.  
Moreover, we observed only a modest (though statistically significant) reduction in the 
magnitude of the gB-CD8+ T cell population in gCp-gB acutely infected TG (8 d.p.i) when 
compared those infected with the rescue virus.  One of the most striking observations was that 
during latency the frequency of gB-CD8 was diminished over time in TG harboring latent gCp-
gB.  Combined with our observation that activated Ova-specific CD8+ T cells that enter the TG 
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during acute infection are lost over time during latency (145), these findings suggest a lack of 
antigenic exposure to gB-CD8 when gB is expressed as a true late gene in gCp-gB. 
Persistent antigenic exposure of gB-CD8 was also suggested by previous studies that 
demonstrated that gB-CD8 in latently infected TG exhibit a more activated phenotype and are 
less reliant on homeostatic proliferation signals than their counterparts in non-infected tissues 
(145).  Here we show that significantly fewer gB- CD8 are positive for intracellular granzyme B 
in TG harboring latent gCp-gB compared to rescuant, even when the load of latent virus was 
equalized.  Since granzyme B represents an activation marker for CD8+ T cells (145, 162), this 
data provides further support for the concept that gB-CD8 receive less antigenic exposure in 
latently infected TG when gB is expressed as a true late gene after viral DNA synthesis. 
Furthermore this data is also consistent with the idea that in wild type infections, sporadic 
expression of gB by reactivating neurons is quickly recognized by gB-CD8 which are then able 
to block reactivation prior to DNA replication.   
We have previously shown that gene expression kinetics are similar during reactivation 
and lytic replication, at least with respect to γ1 (gB) and γ2 (gC) genes (refer Chapter 4). In a 
wild type virus, gB is expressed relatively early so it seems obvious to surmise that gB-CD8 can 
recognize their viral antigen early and shut down reactivation before DNA replication. We 
hypothesized that once DNA replication takes place it is too late in the viral life cycle for CD8+ 
T cells to block reactivation, as the virus has already committed to assembly and egress. 
However, our findings establish that gB-CD8 can indeed block reactivation even after viral DNA 
replication.  This is consistent with the ability of the CD8+ T cell effector molecule IFNγ to block 
reactivation even after late gene expression (31).  CD8+ T cells can employ lytic granules and 
IFN-γ to block reactivation of wild type HSV-1 from latency without neuronal destruction (70).  
It remains to be determined if the effector mechanism(s) employed by gB-CD8 to block 
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reactivation when gB is expressed only after viral DNA synthesis are compatible with neuronal 
preservation.    
The data from this study can be used to design better therapeutic vaccines for HSV-1. 
While CD8+ T cells responding to late antigens are still able to block reactivation, they are not 
retained in high numbers in the TG during latency. This makes late viral antigens a poor choice 
as the sole immunogen. There is an obvious utility to targeting viral proteins expressed before 
DNA replication.  A block in reactivation after viral DNA synthesis would permit an 
accumulation of viral genomes in neurons, which is associated with a greater likelihood of 
reactivation (60). A study by Straus and colleagues demonstrated that the rate of HSV-1 
reactivation is proportional to the number of latent genomes and inversely proportional to the 
number of CD8+ T cells retained in the TG. They therefore suggest that vaccines should be 
evaluated for their ability to induce and maintain a virus-specific CD8+ T cell response as well as 
a low genome load in the ganglia (60). Our findings suggest that immunizing against viral α, β, 
and γ1 proteins that are expressed before DNA replication would optimize the capacity of the 
immune system to maintain HSV-1 in a latent state and prevent recurrent disease.   
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6.0  ANALYSIS OF THE gB-CD8+ T CELL RESPONSE IN C57BL/6 MICE 
THROUGH OVEREXPRESSION OF AND MUTATIONS IN THE 
IMMUNODOMINANT gB498-505 EPITOPE USING RECOMBINANT HSV-1 
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6.1 ABSTRACT 
In HSV-1 latently infected trigeminal ganglia (TG), a small but stable number of CD8+ T cells 
surround latently infected neurons and actively block reactivation. Periodically, external stress 
stimuli can result in loss and dysfunction of some of these TG-resident CD8+ T cells, leading to 
reactivation and recurrent disease. In the absence of an existing vaccine to prevent reactivation, 
we addressed whether it would be possible to augment the antigen-specific CD8+ T cell response 
in the TG to larger numbers. To test this, we exploited the C57Bl/6 mouse model in which 
approximately half of the HSV-specific CD8+ T cells retained in the TG are specific to one 
epitope on glycoprotein B (gB498-505; gB-CD8). We created a recombinant HSV-1 (13LAT) 
which expresses a multimer of thirteen tandem repeats of the gB498-505 epitope from a promoter 
that is highly active during latency (the LAT promoter), thus providing consistent exposure of 
antigen to surrounding CD8+ T cells. Compared to a wild type behaving control virus, 13LAT 
replicated efficiently in the TG and also established latency with similar genome loads. Even 
though 13LAT induced a 2-fold greater total CD8+ T cell response in the TG, the frequency of 
gB-CD8 was not altered by overexpression of these peptides. Furthermore, the greater number of 
CD8+ T cells did not appear to prevent reactivation ex vivo. Since we were not able to induce a 
greater gB-CD8 response or differentiate the gB-CD8 response induced by endogenous gB 
protein and our ectopic peptides present in the 13LAT virus, we engineered new recombinant 
HSV-1 in which the endogenous gB epitope is mutated. We tested four mutant viruses and one 
wild type derivant. While the wild type derivant still induced a gB-CD8 response, all mutant 
viruses were successful in abrogating a gB-CD8 response in the TG. Based on these studies, we 
will rederive the multimer peptide viruses into the background of one of these viruses. This will 
allow us to test the efficacy of our vaccine strategy in the absence of an endogenous gB peptide.  
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6.2 INTRODUCTION 
HSV-1 infections in humans can reactivate frequently and lead to recurrent disease. Primary 
HSV-1 infection of the ocular or orofacial region results in the establishment of latency in the 
trigeminal ganglia (TG). Recurrent reactivation of the virus from the TG results in amplification 
of virus in the periphery where it can cause several complications. Viral replication in the eye 
can lead to a severe immunopathology known as herpes stromal keratitis (HSK). Virus in the eye 
initiates an immune infiltrate into the cornea which can cause disorganization and destruction of 
the collagen matrix of the stroma and the formation of scar tissue (9, 82, 110). Corneal scarring 
resulting from repeated HSK events can ultimately lead to blindness. HSV-1 is the leading cause 
of infectious blindness in the developed world (86).  
Following an HSV-1 infection, CD8+ T cells infiltrate the TG and a maximum infiltrate is 
observed concurrent with the establishment of latency at around 8 d.p.i. The CD8+ T cell 
population then undergoes a massive contraction phase from 8 d.p.i until 34 d.p.i where a small 
but steady population is retained in the TG.  In the latently infected TG, CD8+ T cells polarize 
their TCR toward these neurons and release cytokines and lytic granules into the neurons (67, 
70). TG-resident CD8+ T cells also remain in an activated state during latency suggesting 
exposure to antigen (67). Further proof of antigen exposure comes from studies demonstrating 
the presence of several viral transcripts within latently infected TG in the absence of infectious 
virus (39, 99) . These CD8+ T cells are responsible for maintaining the virus in a latent state and 
their depletion results in reactivation (41). Furthermore, CD8+ T cells maintain HSV-1 latency 
without causing neuronal apoptosis (70). In ex vivo reactivation assays, when TG from 14 d.p.i 
are cultured in the presence of endogenous CD8+ T cells, reactivation is not observed. However, 
when TG from 34 d.p.i are cultured in a similar assay, full reactivation is observed (88). The 
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difference between these two time points is that there are far fewer numbers of CD8+ T cells 
present at 34 d.p.i TG compared to 14 d.p.i. Addition of exogenous CD8+ T cells to 34 d.p.i ex 
vivo cultures successfully prevents reactivation (70). A recent study corroborating this data 
demonstrates that the rate of reactivation is inversely proportional to the number of CD8+ T cells 
retained in the TG and directly proportional to the number of latent genomes (60). In vivo, 
compromising either CD8+ T cell number or function through in vivo depletion or stress 
treatment leads to reactivation (41). Combined, these data demonstrate that during latency, there 
is a delicate balance between viral latency and the number of CD8+ T cells maintained in the TG 
and that functional or numerical impairment of CD8+ T cells or both can lead to reactivation. 
Currently, there is no therapeutic vaccine available for preventing HSV-1 reactivation. 
The concept behind therapeutic vaccines to boost the existing local immunity to HSV-1 such that 
even in times of stress (a common trigger for reactivation), the immune system may prevent full 
viral reactivation or at least limit disease at the periphery. Therapeutic vaccine designs have 
centered on the use of subunit and attenuated live virus vaccines to prevent HSV reactivation. 
While they have demonstrated some efficacy in animal models, they have not been successful in 
human trials (114-115, 134, 160). Subunit vaccine trials in humans were successful in boosting 
neutralizing antibody responses in seropositive individuals but did not reduce shedding rates 
(161). A trial with an attenuated live virus vaccine proved to be safe to use in humans but 
provided no benefit to vaccinated individuals as their shedding rates did not differ from 
unvaccinated individuals. Furthermore, this vaccine did not prevent asymptomatic shedding as 
82% of vaccinated individuals were PCR positive for virus in the periphery (29).  
The use of viral immunodominant peptide epitopes that are recognized by CD8+ T cells 
have been used as immunogens in prophylactic vaccine studies. Tandem repeats of HSV-1 CD8+ 
T cell peptides that were delivered via adenovirus or bacterial vectors were enough to confer 
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protective immunity in challenged mice or minimize viral load at the site of infection (16, 189). 
Transgenic mice or rabbits expressing human MHC molecules have been used recently to study 
the CD8+ T cell response as well as vaccine efficacy in a humanized model (19, 21, 188). In such 
a model, immunization rabbits with known human CD8+ T cell epitopes from seropositive 
individuals induced a strong HSV-1 specific CD8+ T cell response and also reduced HSV-1 
ocular replication and corneal disease after challenge (20). Various adjuvants have been tested to 
maximize effectiveness of vaccine delivery including ligand epitope antigen presentation 
(LEAPS) consisting of a T cell epitope of an HSV-1 protein conjugated to a peptide sequence of 
β-2-microglobulin; localized delivery of epitopes mixed with known immunostimulatory 
molecules such as oligodeoxy-nucleotides (ODNs) induced a strong protective peptide specific 
response and antibody response in animals (46, 114, 136). 
While the studies mentioned above have shown some success as prophylactic vaccines, 
similar strategies have yet to be investigated in the form of therapeutic vaccines. The main 
struggle faced by scientists is to design a vaccine that prevents full reactivation of the virus. A 
vaccine that is able to stop symptomatic shedding, but not able to prevent asymptomatic 
shedding could be detrimental since it would still allow transmission of the virus from person to 
person. Given the strong role for CD8+ T cells to block reactivation, vaccine strategies should be 
aimed at augmenting the existing CD8+ T cell response to HSV-1 in the TG. While boosting the 
overall cellular response to HSV is necessary, more importantly, the local CD8+ T cell response 
at the site of latency has to be augmented. This would be the optimal approach such that in 
situations where function of some of the CD8+ T cells in the TG becomes compromised due to 
stress or other reactivation stimuli, there are enough functional resident CD8+ T cells to 
overcome this dysfunction and still prevent reactivation. In this study, we employ a method of 
overexpressing the immunodominant HSV-1 peptide recognized by C57Bl/6 mice (gB498-505) 
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from recombinant HSV-1 and we assess whether this results in greater antigen-specific CD8+ T 
cell response that can prevent reactivation. 
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6.3 MATERIALS AND METHODS 
6.3.1 Construction and generation of recombinant multimer HSV-1 containing gB498-505 
epitope repeats. 
The recombinant viruses containing gB498-505 epitope repeats were generated on the HSV-1 RE 
background (Fig. 6-1). The primers used to generate the epitope sequence also included the 6 
residues before and 4 residues after the actual epitope region (amino acids: 
RIKKTTSSIEFARLNFTY). The two primers (complementary to each other) used were: gBF 5’ 
GATCCCATGGCGCATAAGACCACCTCCTCCATCGAGTTCGCCAGGCTGCAGTTTACG
TACAACCACAAA 3’  and gBR 5’ GAT CTT TGT GGT TGT ACG TAA ACT GCA GCC 
TGG CGA ACT CGA TGG AGG AGG TGG TCT TAT GCG CCA TGG TGG 3’. The contain 
overlaps of GATC on each end and which represents either a BamHI or a BglII site. The oligos 
were phosphorylated, combined together and heated to 70o C to anneal them to each other. The 
annealed product was then ligated and cut with BamHI and BglII at 37oC for 3 hours to eliminate 
head to head and tail to tail dimmers. The ligated products were run on an agarose gel and the 
bigger DNA bands were cut out (which represent bands containing compatible BamHI ends). 
The multimer fragments were then cloned into a previously described vector, gC-EGFP in which 
EGFP is driven from the gC promoter (31). gC-EGFP was cut with BamHI and the fragments 
containing BamHI ends were ligated into this vector generating a new vector in which the gC 
promoter drove expression of the peptide multimer fragments fused to EGFP. Isolated colonies 
were then tested for inserts that had BamHI at the back end of the insert. Fragments containing  4 
and 13 repeats were sequenced for their integrity (Fig. 6-1B). Into these were insered the 
thymidine kinase (tk) (from Lst-1 plasmid, a kind gift of Neal Deluca), the LAT LAP2 promoter 
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(LAP2 plasmid, a kind gift of Bill Goins) the gB promoter (from our gB-EGFP plasmid detailed 
in Chapter 3), all generated from HinDIII-BamHI cuts from their respective vectors (Fig. 6-1C). 
The resulting plasmids were then cut with HinDIII and NheI and RFP was inserted into them 
generating a final plasmid in which the gC promoter drives expression of RFP and either the tk, 
LAP2 or gB promoters drive the expression of either 4 or 13 repeats of the gB epitope fused to 
EGFP (Fig. 6-1D). The final plasmids were linearized with SspI and cotransfected along with 
HSV-1 RE DNA to generate recombinant plaques. Recombinant viruses were screened by their 
gain of RFP fluorescence and subjected to several rounds of purification. The purified viruses 
were checked for purity by Southern blotting analysis. The multimer repeats were also cloned 
into EGFP-C3 or EGFP-N1 vectors to generate 4 or 13 repeats of the peptide fused to either the 
C-terminus (6C3 or 13C3) or the N-terminus (6N1 or 13N1) of EGFP and expressed under the 
CMV IE promoter. We generated these constructs to test peptide expression in vitro assays. The 
CMV constructs generated are listed in Table 1 and the multimer viruses created are listed in 
Table 2. The above mentioned constructs and viruses were generated by Christina Ferko.  
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Figure 6-1. Construction of gB498-505 epitope multimer viruses. 
A) Representation of the gC-EGFP construct in which EGFP expression is controlled by the gC 
promoter. B) Multimer insertion involved restriction digest of gC-EGFP construct with BamHI 
and insertion of 4 or 13 repeats of the multimer into this site. C) Insertion of various promoters. 
The construct containing the multimers was digested with HinDIII and BgllII and BamHI (tk 
promoter) or BamHI alone (LAP2 and gB promoters). The respective promoters were digested 
with the same enzymes from their parent constructs listed in the materials and methods and 
ligated to create constructs in which the multimer expression was under the control of the tk, 
LAP2 or gB promoters. D) The constructs were then each digested with NheI and HindIII and 
RFP was inserted into the construct. The final construct  was such that the gC promoter drove the 
expression of RFP followed by one of the tk, LAP2 or gB promoters driving the expression of 4 
or 13 repeats of the gB multimer fused to EGFP. The constructs were recombined into the gC 
locus of HSV-1 RE and the recombinant viruses are null for gC protein. The resultant viruses are 
listed in table 2.  
 
 
Table 1. List of multimer constructs under the CMV IE promoter 
Construct EGFP terminus Number of repeats 
4N1 N-terminus  4 
13N1 N-terminus 13 
4C3 C-terminus 4 
13C3 C-terminus 13 
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Table 2. List of multimer viruses 
Virus Promoter Number of repeats 
4LAT LAP2 4 
13LAT LAP2 13 
4TK TK 4 
13TK TK 13 
4gB gB 4 
13gB gB 13 
 
6.3.2 Construction and generation of gB null (gBKO) HSV-1 
We generated gB null viruses that do not express gB Protein. To do this the back end of gB 
(excluding the epitope region) was amplified using the following primers: gBBackF  
5’ GCGCCTAGGCTCGGATCCCAGTTTACGTACAAC 3’ and gBBackR 5’ 
GAGCGGAATTCATTTACAACAAACCCCCCATCA 3’.   
This fragment was cloned into a previously existing plasmid used to make the gC-Rescue in 
Chapter 5. Thus the resulting plasmid contained gB promoter driving the expression of gB and 
had unique BamHI and AvrII sites within the back end of the gB sequence (plasmid 1973) (Fig. 
6-2 i). EGFP was then amplified from EGFP-C3 using the following primers: gBF-EGFP 5’ 
CCC TAG GCT ACC TGA CGG CGG GCA CGA CGG 3’ and 5’ TTG TAC GTA GGA TCC 
TTA CTT GTA CAG CTC GTC 3’. The previous construct was cut with BamHI and AvrII and 
the EGFP amplicon was cloned into that site resulting in a plasmid containing the gB promoter 
driving the expression of EGFP fused to the back end of gB (plasmid 1976) (Fig. 6-2 i). This 
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plasmid effectively does not express functional gB and is missing the epitope region. The 
plasmid was then linearized with an sspI cut and cotransfected into gB-Veros (Veros expressing 
gB from the native gB promoter) along with WT HSV-1 RE genomic DNA. Selection of plaques 
was based on gain of EGFP fluorescence and plaque picks were subjected to several rounds of 
purification (Fig. 6-2 iii). Transfection of gBKO genomic DNA into Veros confirmed the 
absence of functional gB as no plaques were formed in this cell type due to the lack of 
complementing gB to allow viral replication. The gBKO viruses were generated by Kip 
Kinchington and Srividya Ramachandran.  
 
6.3.3 Generation of DNA constructs and recombinant HSV-1 containing mutations in the 
gB498-505 epitope region. 
The gB epitope mutants that were created for this study are listed in Table 3 along with their 
names and respective mutations (in bold and red) that were inserted into the gB498-505 sequence. 
The forward primer used for all constructs was gBFrontF:  
5’  GCCCTAGGCTACCTGACGGGGGGCACGACGGGCCCCCGTAG 3’. 
The reverse primers (gBFrontR) used to generate each of the mutations are listed for each mutant 
in Table 4. The gB front sequence was amplified from HSV-1 RE viral DNA and cloned into a 
pGEM vector for easy selection. Following selection of positive clones and sequencing 
confirmation, each of the mutant constructs were digested with SnaBI and AvrII and ligated into 
the 1976 construct mentioned previously also digested with the same enzymes (1976 construct 
expresses EGFP fused to the back end of gB). The resulting construct now contains gB promoter 
driving the expression of full length gB with the respective mutations in the gB498-505 region (gB-
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plasmids) (Fig. 6-2 iv). The plasmids were also engineered to be expressed under the CMV IE 
promoter for high expression in vitro assays. To do this, the constructs were digested with AvrII 
and EcoRI and ligated into the EGFP-C3 backbone which was cut with NheI and EcoRI 
(dropping out the EGFP sequence). The resulting plasmids contained the gB epitope mutants 
expressed from the CMV promoter (CMV-plasmids).  
In attempting to generate recombinant viruses from the gB-plasmid constructs, we found 
that none of the plasmids yielded viable recombinant plaques. Therefore, to repair the back end 
of these gB constructs, HSV-gCRescue or RE genomic DNA was digested with EcoRI + SnaBI. 
The 6282bp fragment was excised and eluted and then ligated to the 5kb fragment generated 
from a digest of the gB-plasmid DNAs with the same restriction enzymes. The resulting 
constructs were sequentially digested with EcoRI and then HindIII. The 8kb fragment was 
excised, gel-purified, and co-transfected with HSV-gBKO1 infectious DNA in Vero cells. Any 
plaques that formed were pooled and screened by PCR amplification of 500 bp spanning the gB 
promoter and front end of gB ORF containing the unique AvrII site. The PCR products were 
then digested with AvrII to confirm that recombination of the gB-epitope mutant constructs and 
the gBKO DNA had taken place. The epitope mutant constructs were generated by Drew 
Comrey and Michael Yee.  
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Figure 6-2. Construction of gBKO viruses and gB498-505 epitope mutant viruses. 
 
i) Representation of the gC-Rescue construct designed in Chapter 5. The construct was digested 
with AvrII and BamHI and EGFP that was also digested from construct EGFP-C3 with the same 
enzymes was inserted which effectively disrupts the gB ORF. ii) Representation of the HSV-1 RE 
genome highlighting the gB. iii) Representation of the gBnull (gBKO) virus within the gB locus 
of the virus. iv) Representation of the epitope mutant viruses showing the region the mutations 
were inserted. The mutants were generated via recombination into gBKO DNA. The mutants are 
listed in Table 3.  
 
Table 3. List of gB498-505 mutations. 
Number Name Mutation 
1 WT SSIEFARL (none) 
2 L8A SSIEFARA 
3 F5L SSIELARL 
4 S1G GSIEFARL 
5 S1L LSIEFARL 
6 S1G/L8A GSIEFARA 
7 S1G/I3A GSAEFARL 
8 L8A/R7K SSIEFAKA 
9 S1G/I3N/F5L/E4S (SIFE) GSNSLARL 
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Table 4. List of reverse primers used to generate gB498-505 epitope mutants. 
Name Reverse primers used 
WT 5’ GTT GTA CGT AAA CTG CAG CCT GGC 
GAA CTC GAT GGA GGA GGT GGT CTT GAT 
GCG CTC CA 3’ 
L8A 5 ‘ GTT GTA CGT AAA CTG AGC CCT GGC 
GAA CTC GAT GGA GGA GGT GGT CTT GAT 
GCG CTC CA 3’ 
F5L 5’ GTT GTA CGT AAA CTG CAG CCT GGC 
CAA CTC GAT GGA GGT GGT CTT GAT GCG 
CTC CA 3’ 
S1G 5’ GTT GTA CGT AAA CTG CAG CCT GGC 
GAA CTC GAT GGA GGT GGT CTT GAT GCG 
CTC CA 3’ 
S1L 5’ GTT GTA CGT AAA CTG CAG CCT GGC 
GAA CTC GAT GGA CAA GGT GGT CTT GAT 
GCG CTC CA 3’ 
S1G/L8A 5’ GTT GTA CGT AAA CGT AGC CCT GGC 
GAA CTC GAT GGA CCC GGT GGT CTT GAT 
GCG CTC CA 3’ 
S1G/I3A 5’ GTT GTA CGT AAA CTG CAG CCT GGC 
GAA CTC GGC GGA CCC GGT GGT CTT GAT 
GCG CTC CA 3’ 
L8A/R7K 5’ GTT GTA CGT AAA CGT AGC CTT GGC 
GAA CTC GAT GGA GGA GGT GGT CTT GAT 
GCG CTC CA 3’ 
S1G/I3N/F5L/E4S 5’ GTT GTA CGT AAA CTG CAG CCT GGC 
CAA GCT GTT GGA CAA GGT GGT CTT GAT 
GCG CTC CA 3’ 
 
6.3.4 Complementation assay 
Confluent monolayers of Vero cells were transfected with 4µg of plasmids expressing one of the 
epitope knockout gB proteins or wild type gB using the Fugene transfection reagent (Roche 
Diagnostics). After 18 hours, cells were infected with gBKO1 virus at an MOI of 5 for 1 hour. 
Following media replacement, cells were incubated at 37oC for 24 hours prior to harvest. Cells 
and supernatants were harvested and subjected to three freeze-thaw cycles and titrated onto both 
Vero cells and gB-vero cells and counted for plaque forming units.  
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6.4 RESULTS 
6.4.1 Expression of multimers by CMV constructs and recombinant viruses. 
We first tested whether the CMV promoter  expressed constructs (Table 1) and the recombinant 
viruses expressed multimers of the gB peptide (Table 2). We expected a high rate of misfolding 
of these fusion proteins and thus to be targeted to the proteosome for degradation. To block 
proteosome degradation and allow us to detect the fusion peptides via western blots, the 
transfections and infections were allowed to proceed either in the in the presence or absence of 
MG132, a known inhibitor of the proteosome pathway (28, 147). The expected size of the 
expressed peptide fused to EGFP was 35 kDa for 4 repeats of the multimer and and 55kDa for 13 
repeats of the multimer. When fusion peptides were expressed from the CMV IE promoter either 
as C- or N-terminal fusions, we did not observe fragment sizes of the expected sizes. Both in the 
presence or absence of MG132, only a band corresponding to the size of EGFP was observed 
(Fig. 6-3). Even at 48 hours post transfection, there was no accumulation of larger size bands 
(Fig. 6-3 lower panel). Thus it did not appear that the CMV-constructs expressed detectable 
levels of the peptide-EGFP fusion protein or that the amounts of MG132 were not sufficient to 
block proteosome mediated degradation. When the same experiment was performed with the 
recombinant viruses, interestingly we observed a band corresponding to approximately 35 kDa in 
all samples in which MG132 was added (Fig. 6-4). We did not observe the expected 55kDa band 
in cells infected with viruses 13gB and 13TK suggesting that the 35kDa might be a more stable 
form of the fusion peptide. Thus from these assays, we could not conclusively determine whether 
the peptide-EGFP fusion proteins were being expressed correctly.  
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Figure 6-3. Expression of multimer peptides by CMV constructs.  
Confluent Vero cells were transfected with plasmids 4N1, 4C3, 13N1, 13C3, EGFP or left 
untransfected. Media was replaced 4 hours post transfection with or without 20µM of MG132, a 
proteosome inhibitor drug. Cells were harvested for protein 24 or 48 hours later and analyzed by 
immunoblotting for EGFP. The times and drug treatment are shown in the panels above the blots. 
The upper blot represents samples harvested at 24 hours after transfection and the lower blot 
represents samples harvested at 48 hours after transfection.  
 
 
Figure 6-4. Expression of multimer peptides by recombinant viruses.  
Vero cells were infected at an MOI of 5 with 13gB, 13TK, 4gB, 4TK or gC-EGFP for 1 hour at 
room temperature. Media was replaced after one hour with or without 20µM of MG132. Cells 
were harvested at 24 h.p.i and analzyzed by immunoblotting for EGFP.  
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6.4.2 Peptides expressed from the CMV promoter are able to stimulate gB-CD8 to 
produce IFNγ. 
Since we could not confirm expression of the peptides by western blot, we performed an in vitro 
assay to determine if the peptides expressed from the CMV IE promoter could stimulate gB-CD8 
from infected TG of C57BL/6 to produce IFNγ (Fig 6-5). We transfected B6WT3 cells 
(syngeneic fibroblasts from C57BL/6 mice) with the plasmids we created (Table 1) along with 
EGFP as a negative control. We also infected B6WT3 cells with HSV-1 RE (WT) or our control 
virus gC-EGFP and used 18 hour infected cell lysates for this experiment. TG infected for 8 days 
with WT virus were dispersed and combined with transfected or infected cells in the presence of 
golgiplug to allow IFNγ to accumulate within gB-CD8. Both HSV-1 RE and gC-EGFP infected 
cells induced a high IFNγ production by gB-CD8. IFNγ production by cells transfected with 
4N1, 13N1 and 13C3 were comparable to infected cell controls (Fig. 6-3). In contrast, 4C3 did 
not induce an IFNγ response and this response was similar to cells transfected with EGFP which 
served as the negative control. Interestingly, the plasmids containing more number of repeat 
peptides (13N1 and 13C3) did not induce greater IFNγ production by gB-CD8 compared to the 
one containing fewer numbers of repeats (4N1). It is possible that overexpression of these 
plasmids in this transfection assay saturates the amount of peptide synthesized such that plasmids 
expressing more copies of the peptide do not have a greater effect. However, from this 
experiment it can be concluded that while plasmids, 4N1, 13N1 and 13C3 seem to express the 
epitope in frame and induce a strong IFNγ response, plasmid 4C3 was not functional in doing so 
(Fig. 6-5). This demonstrates that plasmids 4N1, 13N1 and 13C3 express the peptides in frame 
which gave us the impetus to continue to characterize the recombinant viruses we created.  
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Figure 6-5. Peptide constructs are able to stimulate gB-CD8 from infected TG to produce 
IFNγ.  
TG were obtained 8 days after corneal infection with HSV-1 RE (WT), dispersed with 
collagenase, and stimulated for 6 h with syngeneic B6WT3 cells that were mock transfected, 
infected with HSV-1 RE, gC-EGFP or transfected with plasmids 4N1, 4C3, 13N1, 13C3 or 
EGFP. Cells were surface stained for CD45 and CD8, and stained for intracellular IFN-γ. The 
graph depicts the mean percent of IFN-γ positive cells (n = 2/group) and standard error of the 
mean for each stimulation. The IFN-γ response of gB stimulated CD8+ T cells from 4C3 and 
EGFP transfections is significantly (p < 0.05) different from the response HSV-RE and gC-EGFP 
as assessed by Students’ t test. 
 
6.4.3 Replication of HSV-13LAT in vivo in the TG is similar compared to gC-EGFP 
For studies in mice, we chose to characterize the 13LAT virus which expresses 13 repeats of the 
peptide fused to the N-terminus of EGFP under the LAT promoter. In our in vitro assay, both 
constructs containing the peptides fused to the N-terminus of EGFP induced an IFNγ response in 
gB-CD8 (Fig. 6-5). Furthermore, during latency, the LATs are the only abundant transcripts to 
be found within infected neurons indicating that this promoter is highly active during latency 
(77). By using this promoter we can predict that there might be persistent expression of the 
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peptides and thus constant antigenic exposure to surrounding CD8+ T cells. Also, by using the 
virus expressing 13 repeats of the epitope, we can maximize antigen presentation to CD8+ T 
cells. We also used a previously defined recombinant HSV-1, gC-EGFP (31) as the control virus. 
gC-EGFP has been shown in previous studies to behave exactly like WT virus in terms of viral 
replication and induction of an immune response. Furthemore, both 13LAT and gC-EGFP 
express fluorescent markers (RFP and EGFP respectively) from the gC promoter allowing us to 
monitor reactivation ex vivo through fluorescent microscopy. 
We first determined the replication kinetics of both 13LAT and gC-EGFP during acute 
phase replication in the TG. At 4 d.p.i which is the peak of viral replication in the TG, both 
13LAT and gC-EGFP viruses grew to equal titers, demonstrating that the additional expression 
of repeat gB epitopes did not impair the ability of 13LAT to access and replicate in the TG (Fig. 
6-6). 
 
Figure 6-6. HSV-13LAT replication in the TG is similar to gC-EGFP.  
Mice were infected with gC-EGFP or 13LAT at 1 × 105 PFU/eye. At 4 d.p.i., TG were excised, 
homogenized and subjected to three freeze–thaw cycles prior to determination of viral titers on 
Vero cells. The graph represents the mean viral titers ± SEM of the mean. Titers of both the  
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viruses in the  TG were not significantly different (p > 0.05) at this time point as assessed by a 
Student's t test (n=10). 
 
6.4.4 HSV-13LAT establishes latency with similar genome copies compared to gC-EGFP 
We next examined the ability of 13LAT to establish latency compared to gC-EGFP. We used 
real-time quantitative PCR to measure the latent genome copies retained in the TG at 34 d.p.i. 
While 13LAT established latency with slightly higher genome copies compared to gC-EGFP, 
this was not statistically significant. Therefore, 13LAT is able to establish latency at similar 
genome copies compared to gC-EGFP (Fig. 6-7).  
 
 
Figure 6-7. HSV-13LAT establish latency with similar copies compared to gC-EGFP.  
Mice were infected  with gC-EGFP or 13LAT at an infectious dose of 1x105 or 3x104 PFU/eye.  
TG were excised at, 34 d.p.i and genome copies were determined by real time PCR. The latent 
viral genome copies retained in TG infected with gC-EGFP and 13LAT are not significantly 
different (p≥0.0.5) as analyzed by a Student’ t-test (n=5). 
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6.4.5 HSV-13LAT induces a greater overall CD8+ T cell response compared to gC-EGFP 
but not a gB-CD8 response in the TG. 
We next assessed the CD8+ T cell response generated in the TG of mice infected with either gC-
EGFP or 13LAT. At 14 d.p.i, both viruses induced a similar total CD8+ T cell infiltrate within 
the infected TG (Fig. 6-8 A). However, by 34 d.p.i, the total number of CD8+ T cells retained in 
the TG of 13LAT infected mice was approximately 2-fold greater than gC-EGFP.  This 
corresponds with the slightly greater (although not statistically significant) number of latent 
genomes retained in TG of 13LAT infected mice compared to those infected with gC-EGFP 
(Fig. 6-7). However, an analysis of the corresponding gB-CD8 response revealed no difference 
in both the total numbers (Fig. 6-8 B) and the frequency of gB-CD8 (Fig. 6-8 C) between the two 
viruses at either 14 or 34 d.p.i. So while 13LAT is able to induce a greater overall CD8+ T cell 
response in the TG, overexpression of the peptide does not appear to alter the gB-CD8 response 
in the latently infected TG.  
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Figure 6-8. Comparison of the CD8+ T cell response within TG infected with gC-EGFP and 
13LAT.  
Mice were were infected with 1 x 105   PFU/eye with gC-EGFP or 13LAT. TG were excised 
at 14 and 34 d.p.i., dissociated into single cell suspensions and surface stained for 
expression of CD45, CD8 and gB498-505-T cell receptor and analyzed by flow cytometry. The 
data are represented as the mean +/- SEM of the mean. The data are combined from two 
independent experiments. A) Total number of CD8+ T cells. The total number of CD8+ T cells at 
34 d.p.i is significantly different between gC-EGFP and 13LAT infected TG (p<0.05) as assessed 
by a Students’ t test. B) The total number of gB-CD8 per TG. C) The percentage gB-CD8 cells 
per TG. For B) and C), the means are not significantly different between gC-EGFP and 13LAT at 
either of the time points tested as assessed by a Students’ t test (p≥0.05).  
 
6.4.6 The frequency of circulating CD8+ T cells in 13LAT infected mice is similar those 
infected with gC-EGFP. 
Since we observed no difference in the gB-CD8 numbers in the TG of 13LAT infected mice, we 
investigated whether this may be due to the inability of gB-CD8 to infiltrate the TG or there were 
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fewer gB-CD8 in the periphery. We did this by measuring the frequency of circulating gB-CD8 
in the blood of infected mice. Both total numbers of CD8+ T cells and gB-CD8 as well as the 
frequency of gB-CD8 were similar in blood of mice infected with either gC-EGFP or 13LAT 
(Fig. 6-9) . Thus 13LAT does not seem to induce a greater gB-CD8 response in the periphery of 
infected mice compared to gC-EGFP. 
 
 
Figure 6-9. Comparison of the CD8+ T cell response within blood of mice  infected with gC-
EGFP and 13LAT.  
Mice were were infected with 1 x 105   PFU/eye with gC-EGFP or 13LAT.  At 34 d.p.i, 100 
ul blood was collected from infected mice and surface stained for expression of CD45, 
CD8 and gB498-505-T cell receptor and analyzed by flow cytometry. The data are represented as 
the mean +/- SEM of the mean. The data are combined from two independent experiments. A) 
Total number of CD8+ T cells. B) The total number of gB-CD8 per TG. C) The percentage gB-
CD8 cells per TG. The means are not significantly different between gC-EGFP and 13LAT for A, 
B or C as assessed by a Students’ t test (p≥0.05).  
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6.4.7 HSV-13LAT reactivation is similar to gC-EGFP 
The use of fluorescent viruses has enabled us to rapidly detect reactivation in vitro by visualizing 
the spread of fluorescence within latently infected TG cultures (31). Both gC-EGFP and 13LAT 
viruses have fluorescence tags that enable us to monitor reactivation through fluorescence 
microscopy. Since 13LAT latently infected TG harbored a larger number of CD8+ T cells 
compared to gC-EGFP, we wanted to investigate if this would result in a lower reactivation 
frequency of 13LAT infected cultures. Examination of ex vivo cultures of TG latently infected 
with gC-EGFP or 13LAT revealed fluorescence plaques that expressed EGFP or RFP 
respectively.  We observed that the percentage of 13LAT cultures that reactivated were slightly 
lower at earlier times post culture, however by 8 days post culture, similar number of cultures 
reactivated for both viruses (Fig. 6-10). Thus the increased number of total CD8+ T cells within 
13LAT infected TG might offer protection from reactivation early, it does not appear to block 
reactivation at later times post culture initiation  compared to gC-EGFP infected TG cultures.  
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Figure 6-10. Reactivation of HSV-13LAT is similar to gC-EGFP. 
TG were excised 34 d.p.i. after corneal infection with gC-EGFP or 13LAT, dispersed with 
collagenase, and cultured (0.2 TG/well) at 37 °C. At the indicated times following culture 
initiation, HSV-1 reactivation from latency was detected based on spread of EGFP fluorescence 
from neurons to surrounding fibroblasts. The mean percent of cultures exhibiting HSV-1 
reactivation from latency and standard error of the mean is shown at each time point.  
 
6.4.8 Alternate strategy for developing recombinant viruses expressing gB multimers. 
The studies described in this chapter so far were not completely successful in identifying whether 
peptide expression could be detected both in vitro and within infected neurons during latency. 
However, the ability of the CMV-constructs to stimulate gB-CD8 indicates that at least in vitro, 
the peptides are expressed in frame, undergo the proteosome pathway and are presented on 
MHC-I molecules for presentation to CD8+ T cells. We also did not observe a difference in the 
gB-CD8 response generated by gC-EGFP or 13LAT infections and therefore could not determine 
whether the peptides were being expressed during latency. Since the 13LAT virus also contains 
an existing endogenous gB epitope present within the native locus, we were unable to 
differentiate the gB-CD8 response generated from this epitope from the ectopically expressed 
peptides. Thus we had to formulate an alternative strategy to address this question. This required 
the engineering of several additional recombinant viruses. First we generated a virus in which the 
gB gene is abrogated such that it does not express native gB protein. Using this virus as a 
backbone, we then engineered several viruses containing mutations in the epitope region which 
would restore fully functional gB protein into the virus but abrogate recognition of the gB498-505 
peptide by gB-CD8 (gB-epitope mutant viruses). The following studies describe the generation 
and characterization of these viruses both in vitro and in vivo. Future studies will involve the re-
engineering of the multimer viruses into the gB-epitope mutants, thus allowing us to address 
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whether overexpression of CD8+ T cell peptides can induce an antigen-specific CD8+ T cell 
response within latently infected ganglia.  
6.4.9 HSV-gBKO viruses do not express glycoprotein B. 
We independently isolated two HSV-gBKO viruses. Our strategy involved recombination of 
EGFP into the front end of gB such that the resultant viruses were fluorescent but did not express 
functional gB. Since gB is an essential viral protein required for virus entry and replication, 
selection for recombinants had to be performed in a complementing cell line containing a 
plasmid expressing gB from the native gB promoter (gB-Veros) (Fig. 6-2). To confirm that our 
gBKO viruses were null for gB protein and that recombination between gBKO DNA and the gB 
plasmid from the gB-Veros did not occur, we analysed gBKO infected lysates for gB expression 
by western blot. Vero cells infected with an MOI of 10 with WT-RE, gBKO1 or gBKO2 were 
harvested at 1, 12 and 24  h.p.i and analysed for gB expression. At both 12 and 24 h.p.i, WT RE 
expressed high levels of gB but this expression was not observed in either gBKO1 or gBKO2 
infected cell lysates indicating that both these viruses do not express gB (Fig. 6-11 top panel). A 
western blot analysis using anti-HSV antibody revealed a similar pattern of protein expression 
indicating that the gBKO viruses were not defective in synthesizing other viral proteins (Fig. 6-
11 bottom panel).  
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Figure 6-11. HSV-gBKO1 and HSV-gBKO2 viruses do not express any gB protein.  
Confluent monolayers of Vero cells were infected with an MOI = 10 with HSV-1 RE, gBKO1 
and gBKO2 or mock infected. Total SDS PAGE separated proteins were analyzed by 
immunoblotting for using polyclonal antibodies to gB and HSV. The times of harvest are 
indicated above each lane. The top panel represents an immunoblot for gB and the bottom panel 
is for total HSV proteins.  
6.4.10 The gB498-505 epitope mutant DNA constructs are unable to stimulate gB-CD8 to 
produce IFNγ. 
The gB498-505 epitope mutant DNA constructs were tested for their ability to stimulate WT gB-
CD8 to produce IFNγ. For this assay, we used gB-CD8 that were expanded in vitro from TG 
latently infected with WT virus. The positive control (gB) in which gB is expressed in high 
amounts from a CMV promoter stimulated gB-CD8 to high levels. In contrast, none of the 
epitope mutant constructs were able to stimulate gB-CD8 and the levels of IFNγ production were 
similar to mock transfected cells (Fig. 6-12 top panel). gB expression was confirmed for all 
constructs via western blotting (Fig. 6-12 bottom panel). The WT condition represents a 
construct which was made simultaneously with the epitope knockout constructs but in which the 
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epitope was not disrupted. Stimulation of gB-CD8 with the WT construct was similar to the 
positive gB control demonstrating that the strategy used to generate these constructs maintained 
the integrity of the protein and allowed it to be expressed in frame (Fig. 6-12 top panel).  
 
`   
Figure 6-12. gB498-505 epitope mutant constructs are unable to stimulate gB-CD8 to produce 
IFNγ. 
B6WT3 (1 x 105 cells) were transfected with 5µg of plasmids expressing one of the gB epitope 
mutant proteins or wild type gB. 18 hours post transfection, cells were combined with 5 x 104 gB-
CD8 and stimulated for 6h in the presence of golgiplug. Cells were surface stained for CD45 and 
CD8, and stained for intracellular IFN-γ. The graph depicts the mean percent of IFN-γ positive 
cells (n = 2/group) and standard error of the mean for each stimulation. The bottom panel 
represents an immunoblot for gB confirming protein expression within each transfection.  
 
6.4.11 The gB498-505 epitope mutant DNA constructs are able to complement gBKO virus 
growth 
Prior to generating recombinant viruses using each of the epitope mutant constructs, we 
performed complementation assays to determine whether these mutations generated within the 
gB protein had any effect on its function. Vero cells were transfected with each of the plasmids 
and 18 hours later infected with the gBKO1 virus at an MOI of 5. Cells were harvested 48 hours 
later and titrated on both Veros and gB-Veros. None of the conditions produced plaques on 
Veros (not shown) demonstrating that recombination between the transfected plasmids and 
gBKO1 virus did not occur and also that gBKO1 virus is truly null for gB expression. Both 
untransfected and EGFP transfected controls produced no plaques when titrated on gB-Veros 
demonstrating that the gBKO1 virus was unable to replicate and amplify itself within infected 
Vero cells (Fig. 6-13 top panel). Complementation with the positive control gB plasmid resulted 
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in high virus titers up to 107 PFU/ml (Fig. 6-13 top panel). Compared to this, all the epitope 
mutant constructs were able to complement the gBKO1 virus but to varying levels. Both 
S1G/I3A and S1G/L8A mutants were able to complement the gBKO1 virus similar to levels seen 
with the positive control. The F5L and L8A/R7K mutants were also able to complement the 
gBKO1 virus, they yielded virus titers that were approximately 2 log lower than the positive 
control. The remaining plasmids were able to complement the gBKO1 virus to about 1 log lower 
than the positive control (Fig. 6-13 top panel). Expression of gB from all transfections was 
confirmed via western blotting (Fig. 6-13  bottom panel).  
 
Figure 6-13. gB498-505 epitope mutant constructs are able to complement the gBKO virus.  
 
Confluent Vero cells were transfected with one of the above plasmids or left untransfected. 18 
hours later, cells were infected with gBKO1 virus at an MOI of 5. 24 hours post infection, cells 
and supernatants were harvested, subjected to three freeze-thaw cycles and titrated on to Vero 
cells. The graph represents the plaque forming units (PFU)/ml calculated for each virus after 
titration onto Vero cells. The bottom panel represents an immunoblot of gB confirming protein 
expression from each transfection.  
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6.4.12 Replication of gB498-505 epitope mutant viruses in the TG. 
We next wanted to text viral pathogenicity and replication of some of the epitope mutant viruses 
in C57BL/6. For this chapter, only WT, F5L, L8A, S1L and SIFE mutants were tested in 
C57BL/6 mice as those were the viruses available at the time the experiment was performed. We 
measured the viral titers in the TG at 4 d.p.i which is normally the peak of viral replication in the 
TG (refer to Chapters 4 and 5). Surprisingly, the WT control did not replicate as efficiently in the 
TG as expected (Fig.6-14). This might indicate that during the isolation process, an unknown 
mutation was introduced into the WT recombinant which affects its pathogenicity. Interestingly, 
the F5L mutant grew to high titers in the TG, similar to levels observed with wild-type or rescue 
viruses in our previous studies (refer to Chapters 4 and 5). Both the L8A and S1L mutants were 
similarly impaired compared to the WT and the SIFE mutant produced no plaques at all. This 
shows that the F5L mutation in gB does not compromise the ability of this virus to replicate in 
the TG (Fig. 6-14).  
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Figure 6-14. Replication of gB498-505 epitope mutant viruses in the TG.  
Mice were infected with 1 x 105 PFU/eye with HSV-1 WT, HSV-1 L8A, HSV-1 S1L, HSV-1 
F5L or HSV-1 SIFE. At 4 d.p.i, TG were harvested and subjected to three freeze thaw cycles and 
infectious virus released into the supernatant was titrated on to Vero cells. The graph represents 
the mean virus titer for each virus ± SEM of the mean (n = 5 mice).   
 
 
 
6.4.13 The gB498-505 epitope mutant viruses do not induce a gB-CD8 response in the TG 
The main goal in generating the epitope knockout viruses was to abolish their ability to induce a 
gB-CD8 response in the TG of C57BL/6 mice. Thus we measured the CD8+ T cell response 
generated in mice infected with WT, L8A, F5L, S1L and SIFE mutants at 14 d.pi (Fig. 6-15). 
Concordant with their poor ability to replicate in the TG, the WT, L8A, S1L and SIFE mutants 
all generated a very poor total CD8+ T cell response in the TG (Fig. 6-15 A). In contrast, the total 
CD8+ T cell infiltrate in the TG of F5L infected mice was greater, similar to numbers observed 
previously using wild type viruses (refer Chapters 4 and 5). However, when we measured the 
total and frequency of gB-CD8 in the TG of infected mice, we observed a significant number of 
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gB-CD8 in TG of mice infected with WT but very few gB-CD8 in TG of mice infected with the 
L8A, S1L, SIFE or F5L mutants (Fig. 6-15 B). When this was translated to the frequency of gB-
CD8 in the TG, as expected, approximately 40-45% of the total CD8+ T cells in WT infected TG 
were gB-CD8. In contrast to this, the percentage of gB-CD8 in the L8A, S1L, SIFE or F5L 
infected TG represented around or less than 5% of the total CD8+ T cells (Fig. 6-15 C). This 
demonstrates that the L8A, S1L, SIFE and F5L mutants did not generate a significant gB-CD8 
infiltrate within infected TG while the WT virus does (Fig. 6-15). 
 
Figure 6-15. Comparison of the CD8+ T cell and the gB-CD8 response within TG infected 
with gB498-505 epitope mutant viruses.  
Mice were were infected with 1 x 105   PFU/eye with HSV-1 WT, HSV-1 L8A, HSV-1 S1L, 
HSV-1 F5L or HSV-1 SIFE. TG were excised at 14 d.p.i., dissociated into single cell suspensions 
and surface stained for expression of CD45, CD8 and gB498-505-T cell receptor and analyzed by 
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flow cytometry. The data are represented as the mean +/- SEM of the mean. A) Total number of 
CD8+ T cells.. B) The total number of gB-CD8 per TG. C) The percentage gB-CD8 cells per TG.  
 
 
 
 
 
 
 
6.5 DISCUSSION 
Currently, there is no available vaccine to prevent HSV-1 reactivation. Therapeutic vaccine trials 
in both animals and humans have been successful in boosting the cellular and antibody responses 
in the periphery but have not been effective in augmenting the existing CD8+ T cell response at 
the site of latency. While an increased immune response in the periphery can act to minimize 
viral shedding and transmission, it is not able to prevent reactivation of the virus entirely and 
thus cannot prevent recurrent disease. Many prophylactic vaccine trials in animal models have 
been successful in the use of CD8+ T cell epitope peptides as immunogens to prevent or reduce 
the severity of an initial HSV-1 infection. In the absence of an available vaccine to prevent HSV-
1 reactivation, we sought to use a similar approach to design a novel vaccine strategy in which 
we could augment the existing CD8+ T cell immunosurveillance at the site of latency. In this 
study, we exploited the C57BL/6 mouse model in which, the gB498-505 peptide represents the 
immunodominant epitope recognized by virus-specific CD8+ T cells following infection. In the 
C57Bl/6 mouse, approximately a thousand CD8+ T cells are retained within the latently infected 
TG at 34 d.p.i and beyond. Out of these, approximately half represent gB-CD8. We thus assessed 
whether a recombinant HSV-1 which expresses tandem repeats of the viral gB498-505 epitope 
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could induce a larger gB-CD8 response in the TG during latency, which would be able to prevent 
reactivation.  
Our strategy was to augment the CD8+ T cell response in the ganglia by overexpressing 
the gB498-505 epitope within latently infected neurons. We first generated several constructs 
containing either 4 or 13 tandem repeats of the gB498-505 peptide fused to EGFP. In our initial 
studies characterizing peptide expression in vitro, we did not observe the expected size fragment 
of the fusion peptides in a western blot assay (Fig. 6-3 and Fig. 6-4) but constructs expressing the 
peptides were able to stimulate gB-CD8 to produce IFNγ confirming that the peptides were being 
expressed in frame (Fig. 6-5). We note that the constructs expressing more numbers of peptide 
repeats did not induce a greater IFNγ response compared to ones expressing fewer numbers of 
repeats. This assay required expression of peptides via a transfection assay which often results in 
overexpression of proteins. It is possible that the high amount of peptide expressed within each 
transfection, saturated the assay to a level that made it impossible to determine differences in the 
level of stimulation by cells expressing 4 or 13 repeats of the epitope. 
Following the above mentioned studies, we generated several viruses in which tandem 
repeats (4 or 13) of the epitope were expressed from the the LAT (LAP2), gB or tk promoters 
(Table 2). However, we only characterized the virus expressing 13 repeats of the epitope from 
the LAP2 promoter (HSV-13LAT) in vivo. During latency, the only transcripts to be expressed in 
high amounts are the LATs and the LAT promoters are highly hyperacetylated, demonstrating 
active transcription (77). Thus we chose to evaluate this virus so that there is persistent exposure 
of viral antigen to surrounding CD8+ T cells. The 13LAT virus was able to replicate efficiently 
in the TG  to the control (gC-EGFP) demonstrating that the addition of exogenous peptides had 
no detrimental effects on viral pathogenesis. Real time PCR analysis of the latent genomes 
revealed a slightly greater (although not significantly different) number of latent genomes 
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retained in TG of mice infected with the 13LAT virus compared to gC-EGFP. However, since 
the assay was only limited to five mice, it is not possible to conclude from this data set whether 
this small increase in genome copy number could be significant in future experiments. A greater 
overall CD8+ T cell response (2-fold increase) was observed in TG infected with 13LAT 
compared to gC-EGFP which could have been contributed by the greater number of genomes 
retained in 13LAT infected mice. However, we did not observe a greater gB-CD8 response in 
13LAT infected mice. It is possible that during the recombination process, an unknown mutation 
could have been introduced into these viruses thus shifting them out of frame making them non-
functional. Studies in chronic viral infection models have demonstrated CD8+ T cell exhaustion 
resulting from high levels of antigen exposure and in some extreme cases, even deletion of 
antigen-specific CD8+ T cells (42, 111, 183). It is possible in our study that by expressing the 
peptides from the LAP2 promoter, there is overexposure of this antigen to gB-CD8 and instead 
of inducing a greater gB-CD8 response it leads to their exhaustion or depletion from the TG. In 
future studies, we will explore the use of the viruses in which the peptides are expressed from the 
gB and tk promoters. Since these promoters will be active only periodically when the virus is 
attempting to reactivate, antigen expression from these promoters may not overwhelm the 
immune response.  
Our overall goal with using the peptide viruses is to determine if they are useful as 
vaccine strategy to block reactivation. A disadvantage in performing these studies in C57BL/6 
mice is that it is nearly impossible to induce reactivation in vivo in this mice strain. While a 
reactivation stimuli or administration of anti-CD8 antibody results in an increase in copy number 
within latently infected TG, we have never been able to detect infectious virus either in the TG or 
in the cornea. Reactivation studies must be performed using ex vivo assays which require far 
greater numbers of CD8+ T cells to prevent reactivation compared to that needed in vivo. For 
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these reasons, it is difficult to assess vaccine efficacy as we cannot evaluate whether vaccinated 
mice can be protected from induced reactivation in vivo.  Our future vaccines studies might be 
performed in BALB/b mice which mount a CD8+ T cell immune response identical to C57BL/6 
mice. Since these mice have a BALB/c background, inducing reactivation in vivo may also be 
possible (117). This will allow us to induce reactivation in vivo and test vaccine efficacy by 
measuring both increases in copy number and infectious virus production. Furthermore these 
mice develop HSK similar to BALB/c mice and any vaccine strategy can also be assessed by its 
ability to reduce HSK in these mice.  
Since we did not observe a difference in the gB-CD8 infiltrate in TG of mice infected 
with HSV-13LAT compared to the gC-EGFP control, we could not determine whether 
overexpression of the epitope region was functional in this virus. For this reason, we chose an 
alternative strategy in which the native gB epitope had been mutated such that induction of a gB-
CD8 response was abrogated. We tested four mutant viruses HSV-L8A, HSV-S1L, HSV-F5L 
and HSV-S1G/I3N/F5L/E4S (HSV-SIFE) and one wild type (WT) derivant that were available at 
the time the experiments were performed. Interestingly, even though gB protein expressed from 
all the epitope mutant DNA constructs were able to complement gBKO virus in an in vitro 
complementation assay, different growth properties of the corresponding recombinant viruses 
were observed in vitro. Interestingly, the WT virus showed some growth deficiency in the TG at 
4 d.p.i., indicating that an unknown mutation could have been introduced into the virus that 
compromised its pathogenicity. Out of the four other mutants tested, HSV-F5L virus replicated 
the best in the TG and demonstrated titers in the TG similar to those seen with wild type viruses 
from our previous studies (refer to Chapter 4 and 5). It is possible that the growth impairment 
seen for HSV-L8A, HSV-S1L and HSV-SIFE could also be due to an unknown mutation 
introduced into the viruses during the recombination process. However, despite the growth 
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impairment of the WT derivant, viral infection still induced a large frequency of gB-CD8 in the 
TG (~45%) which is typical of wild type viruses (67). In contrast, TG infected with the four 
mutant viruses did not demonstrate a similarly great gB-CD8 response. Interestingly, in mice 
infected with the mutant viruses, there were still a small percentage of CD8+ T cells that could be 
detected by gB498-505-tetramer staining. These cells could reflect CD8+ T cells of an alternative 
specificity (not wild type gB498-505) in which the epitope is close enough to gB498-505 that the 
tetramer staining is still able to bind and detect some of these CD8+ T cells. Alternatively, the 
mutations made in each of the viruses were not sufficient in completely ablating the activation 
and expansion of gB-CD8. Since unexpectedly, the WT control virus did not show the robust 
growth properties we expected in vivo, it is difficult to fully and comprehensively interpret the 
data from the above mentioned experiments. However, since HSV-F5L was not compromised in 
its replication in the TG and did not induce a significant gB-CD8 response, a rescue virus will be 
derived from the F5L background which will be used as our control. This will help us understand 
whether this viral backbone contains some other mutation that makes it more pathogenic and will 
ultimately serve as the true control for the HSV-F5L virus. We expect the rescuant to be fully 
replication competent in vivo comparable to the parental virus, HSV-1 RE. Once the replication 
kinetics of HSV-F5L and its corresponding rescuant have been established, we will derive new 
recombinant viruses containing the peptide repeats in the absence of an endogenous gB498-505 
response. This will allow us to determine whether expression of the gB epitope from an ectopic 
site will induce a gB-CD8 response in the TG and also allow us to determine whether the number 
of repeats (4 or 13) has any effect on the magnitude of this response.  
The studies characterized in Chapter 5 demonstrate that while CD8+ T cells responding to 
late antigens are able to block reactivation, they are not retained in high numbers in the TG 
during latency. Previous studies have demonstrated the non-gB498-505 population of CD8+ T cells 
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is also HSV-specific and can block reactivation. However the identity of these CD8+ T cells is 
currently unknown. The F5L mutant virus will prove useful in determining the epitope 
specificity of the other CD8+ T cells. By comparing the identity of the non-gB498-505 CD8+ T cell 
repertoire generated in a wild type infection to that generated in the F5L mutant, we will be able 
to determine whether the repertoire is altered in the absence of the immunodominant gB498-505 
epitope. This will help us further our understanding on how CD8+ T cells specific to 
immunodominant epitopes influence the infiltration and retention of those specific to non-
immunodominant epitopes. Furthemore, the identity of the alternate CD8+ T cell epitopes will 
also shed light on which viral antigens CD8+ T cells respond to and the mechanisms involved in 
blocking reactivation.  
While these studies will help us understand the dynamics of how CD8+ T cell responses 
develop and are maintained in the murine ganglia, translation of this work to human studies will 
prove to be more challenging. In our studies in mice, our aim is to show a proof of principle that 
by expressing multiple copies of a particular CD8+ T cell epitope, we can augment the immune 
response to that antigen and subsequently prevent reactivation. However, since humans do not 
react to the same CD8+ T cell epitopes, the challenge facing scientists is to be able to predict 
viral epitopes that are reactive in humans. The dynamics of how pre-existing memory CD8+ T 
cells react to reactivating virus is also not fully understood. Knowledge on how the existing 
CD8+ T cell memory population is boosted in response to reactivation is needed to design better 
vaccines. Also, since therapeutic vaccines would need to be delivered locally to the site of 
latency, an effective and safe method of delivery needs to be generated. The use of live virus 
may not be a viable option due to safety concerns. While the use of a replication defective HSV-
1 viral vector would be useful in that there would be constant antigen presentation to surrounding 
CD8+ T cells, there is still the risk of viral reactivation from the vaccine virus, which could 
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exacerbate any existing disease. Use of an appropriate adjuvant seems to play a critical and 
important part in the efficacy of a vaccine. While vaccination with peptide vaccines along with a 
strong adjuvant would boost the immune response temporarily, repeated vaccinations may be 
necessary. However, knowledge of the importance of the cellular immune response in the control 
of HSV-1 infection and reactivation has led to several animal studies involving vaccines aimed at 
eliciting such a response, such as DNA vaccines and vaccines encoding cytokines. The future of 
HSV-1 therapeutic vaccines may lie in these new techniques. 
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7.0  CONCLUSIONS AND FUTURE DIRECTIONS 
The work presented in this thesis has significantly improved our knowledge on HSV-1 latency 
and how CD8+ T cells responds to viral infection. Previous to this work, a strong role for CD8+ T 
cells in controlling of viral latency had been established (66, 87-88); however it was not clear 
how HSV-1 antigen expression during latency and reactivation influenced the way CD8+ T cells 
responded to virus in latently infected ganglia. Using HSV-1 gB and gC as representative early 
and late viral antigens, we show that during reactivation events, gB expression occurs much 
sooner than gC expression, indicating lytic replication kinetics are maintained during 
reactivation. We also show that CD8+ T cells responding to late antigens are not retained in high 
numbers in latently infected TG, but are still capable of  blocking reactivation indicating they can 
act very quickly even after DNA replication. Finally, by mutational analysis of a HSV-specific 
CD8+ T cell peptide, we show that CD8+ T cells responding to the original peptide do not 
infiltrate the TG. These studies all demonstrate that during an HSV-1 infection, only antigen-
specific CD8+ T cells infiltrate the TG and antigen exposure during latency is responsible for 
their retention in the TG. This work has great implications toward designing better immuogens 
for therapeutic vaccines to prevent HSV-1 reactivation. 
The studies performed in Chapter 4 describe the development and use of a novel 
recombinant HSV-1 which expresses two fluorescent proteins from two different lytic promoters.  
We chose the gB and gC promoters as typical γ1 and γ2 promoters to drive EGFP and RFP 
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expression respectively. The recombinant virus pgB/pgC replicated efficiently in culture and in 
vivo and induced an immune response similar to wild type virus. This virus also reactivated to 
similar levels as wild type HSV-1, expressing high levels of EGFP and RFP. Previous to this 
study, it was not clear whether lytic gene expression kinetics were maintained during latency. 
We show that EGFP expression (from γ1 gB promoter) occurs much sooner than RFP expression 
(from γ2 gC promoter) in ex vivo cultures demonstrating kinetic activity comparable to lytic 
replication. The highly activated phenotype of gB-CD8 in latently infected TG of C57BL/6 mice 
also led us to investigate if we could visualize antigen expression during latency. We wanted to 
determine if we could capture EGFP expression from the gB promoter in the absence of RFP 
from the late gC promoter. However, whole mount analysis of latently infected TG did not reveal 
either EGFP or RFP expression. It is possible that extremely low level EGFP expression was 
below our level of detection via confocal imaging. For ease of recombination, we had chosen to 
insert the gB-EGFP-gC-RFP cassette into the gC locus since gC is not essential for replication 
(52). Since DNA replication does not occur during latency and lytic genes are hypermethylated 
to maintain latency (179), it is also possible that gene expression from this locus was silenced in 
our recombinant virus. Therefore, during latency the gB promoter may be periodically active 
from its native locus, this activity could have been repressed within the gC locus due to histone 
modifications or due to the presence of repressors. This silencing was de-repressed when we 
treated latently infected mice with sodium butyrate, a histone deacetylase inhibitor and a known 
inducer of HSV-1 reactivation. Whole mounts of TG from treated mice demonstrated high levels 
of both EGFP and RFP expression. Therefore, while this virus remains a powerful tool to study 
gene expression during lytic replication and reactivation, our strategy did not allow us to observe 
gene expression during latency. A previous study showed the ability of IFNγ to block 
reactivation both before and after DNA replication in separate cultures using single fluorescent 
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viruses (31). By co-culturing latently infected TG with HSV-specific CD8+ T cells, we can 
determine the frequency of cultures in which reactivation is stopped prior to DNA replication 
(gB-EGFP expression only) and in which reactivation is stopped following DNA replication (gB-
EGFP and gC-RFP expression). This will further our understanding of how quickly CD8+ T cells 
respond to reactivating virus and the mechanisms involved in blocking reactivation.  
Following the previous study, we used an alternative approach to determine whether 
antigen expression occurred during latency and more importantly, how important this was to 
maintain an antigen-specific CD8+ T cell response in the TG. Our observation that a stable 
number of HSV-1 genomes are maintained during latency led us to hypothesize that DNA 
replication did not occur during latency and consequently, γ2 proteins should not be expressed 
during this time. Using gB as our model antigen, we altered its expression from a γ1 protein that 
is expressed early during infection to one that is dependent on DNA replication. Surprisingly, 
this recombinant virus (gCp-gB) grew very poorly in vivo in infected TG. Several roles for gB 
have been implicated including viral entry, counteracting host response and viral egress (52, 113, 
185). Therefore, altering gB expression seems to severely diminish viral growth, underscoring 
the importance of early gB expression for viral replication. The gB-CD8 infiltrate into the TG 
during latency was substantially diminished compared to the rescue virus. This phenomenon was 
not due to the inability of this virus to generate a gB-CD8 response in the lymph nodes or due to 
its poor growth. During the acute stages of infection, the infiltrating gB-CD8 in gCp-gB infected 
TG showed activation levels similar to the gB-CD8 in Rescue infected TG further demonstrating 
they were once exposed to high levels of antigen during acute infection. However, these gB-CD8 
in gCp-gB infected TG fail to maintain this activated phenotype during latency (34 d.p.i) 
indicating the loss of antigen exposure during this time. These experiments show that periodic 
anrtigen exposure during latency is responsible for maintaining an activated, antigen-specific 
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CD8+ T cell infiltrate in the TG that is capable of blocking reactivation. Future studies will 
involve a further analysis of the phenotype of the infiltrating gB-CD8. One of the more 
interesting aspects of this study was that viral latency is still maintained in the absence of a 
predominant gB-CD8 response. A small percentage of gB-CD8 are still retained in the TG and 
the proportion of gB-CD8 T cells reduces over time indicating that some other population of 
HSV-specific CD8 T cells may be expanding to take up the space created from the loss of the 
gB-CD8. A previous study has shown that the non-gB-CD8 population is also HSV-specific and 
able to block reactivation (145). It will be important to determine which viral antigens the non-
gB-CD8 population responds to in gCp-gB infected TG and how the range specificity is affected 
when immunodominance is altered. In these studies we have not thoroughly explored the 
phenotype of the existing gB-CD8 in gCp-gB infected TG and whether they are functional in ex 
vivo assays. Sorting gB-CD8 from non-gB CD8 and performing ex vivo proliferation assays in 
response to antigen can give us a better idea of whether these cells are still functionally 
competent even though they are not exposed to high levels of antigen in vivo. The inflammatory 
environment of the TG latently infected with gCp-gB may be different from Rescue infected TG 
with respect to chemokine expression and dependence on cytokines such as IL-15 for attraction 
and survival of CD8+ T cells in the TG. Future studies will involve characterizing these specific 
differences to further understand whether they are a contributing factor to the diminished gB-
CD8 response seen in gCp-gB infected mice.  
Interestingly, in ex vivo reactivation assays, gB-CD8 maintained their ability to block 
reactivation of gCp-gB infected cultures indicating that CD8+ T cells can act very quickly, even 
after DNA replication. They may be able to act at a late stage by blocking viral assembly or even 
egress of the virus from infected cells. Future studies could involve understanding which viral 
protein functions are altered in the presence of CD8+ T cells responding to reactivation. 
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Immunofluorescence imaging could reveal a differential localization of proteins involved in 
assembly or egress. It will be important to understand which stage of viral replication CD8+ T 
cells act to block reactivation. Using chamber systems in which the soma and axons of neurons 
are separated, it will be important to determine whether assembly or trafficking of virus is 
affected in the presence of CD8+ T cells.  It is also possible that some late proteins are degraded 
by granzymes thus affecting the structural integrity of replicating virus. The importance of 
perforin and granzymes in blocking reactivation of also needs to be explored by using gB-CD8 
missing one or both of these components.  Performing ex vivo reactivation assays with TG 
cultures latently infected with gCp-gB or the dual fluorescent virus in the presence of granzyme 
or perforin null gB-CD8 will give us a better idea of which stage in reactivation these 
components are able to act on.  
In order to design a novel vaccine strategy to prevent HSV-1 reactivation, we generated 
several recombinant viruses that expressed multiple copies of the immunodominant gB498-505  
CD8+ T cell epitope from various HSV-1 promoters. Our strategy was to overexpress the epitope 
such that a greater gB-CD8 infiltrate was retained in the TG, capable of blocking reactivation 
upon stress stimuli. We tested one of the recombinant viruses in vivo that expressed thirteen 
repeats of the peptide from the LAT promoter (HSV-13LAT). While this virus demonstrated 
replication kinetics similar to the control, the gB-CD8 response was not greater in HSV-13LAT 
infected TG compared to the control. We then speculated that the endogenous gB protein was 
expressed to such high levels that the gB-CD8 response generated from the protein masked any 
gB-CD8 infiltrate induced by peptide expression. We then adopted a new strategy in which we 
generated a panel of mutant viruses in which the gB498-505 epitope was abrograted such that it did 
not induce an appreciable gB-CD8 response within infected TG. We tested a subset of our 
recombinants in mice and observed that one mutant (gB-F5L) replicated to similar levels as a 
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wild type virus indicating that this mutation did not affect gB function or viral growth. In 
contrast to wild type viruses, the gB-CD8 infiltrate within TG of mice infected with gB-F5L was 
less than 2% of the total CD8+ T cells. This gives us confidence that this virus does not induce a 
gB-CD8 infiltrate into the TG and we can now use this virus to re-derive the multimer viruses 
into this background. This will allow us to test these viruses in mice and observe whether we 
generate a gB-CD8 response simply by expressing CD8+ T cell epitopes. It might also be 
worthwhile to move our studies into Balb/B mice which mount an immune response similar to 
C57BL/6 mice but unlike C57BL/6 mice, reactivation can be induced in Balb/B mice. Following 
that we can determine whether the number of epitopes has an affect on the magnitude of the gB-
CD8 response. Finally, in Balb/B mice, we can ask the question whether a greater gB-CD8 
response in the TG is capable of blocking reactivation in vivo, as a therapeutic vaccine strategy. 
Using the epitope mutant viruses (especially HSV-F5L) we can also try and determine the 
identity of other antigen-specific CD8+ T cells retained in the TG. Following wild-type infection, 
all the CD8+ T cells retained in the TG are HSV-1 specific and can block reactivation. It will be 
interesting to investigate how the range of specificities of the infiltrate will be altered in the 
absence of the immunodominant gB epitope. It is possible that other epitopes that were 
previously sub-dominant will now become predominant and occupy a larger proportion of the 
repertoire of the TG-resident CD8+ T cells. The identity of these previously unknown epitopes 
will further our understanding on how antigen expression affects the development and retention 
of antigen-specific CD8+ T cells in the TG. 
The work presented here has given us significant insight on HSV-1 replication and on 
how HSV-1 influences the development and retention of antigen-specific CD8+ T cells in 
latently infected TG. The ultimate goal of this research was to understand which immunogens 
would be the best choice to use in therapeutic vaccines. Our studies show that proteins expressed 
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early in infection and reactivation are more potent inducers of a CD8+ T cell response and 
therefore make better candidates as therapeutic vaccine targets. While translating this work to 
human studies will require significant amount of work in terms of the best vaccination approach, 
it gives us a strong foundation towards developing an effective vaccine against HSV-1. 
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